Access DB# 90823

SEARCH REQUEST FORM

Scientific and Technical Inf rmation Center

Requester's Full Name: Jeffrey Srew Examiner #: 74907 Date: 4/7/03
Art Unit: 1637 Phone Number 30 5-3886 Serial Number: 09/835371
Mail Box and Bldg/Room Location: 10 B 03 Results Format Preferred (circle): PAPER DISK E-MAIL

If mor than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Polyamide Nucleic Acid Derivatives

Inventors (please provide full names): Uhlmann

Earliest Priority Filing Date: 4/17/01

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**

elected Gaps 1-25, 30-32, 40-80

When done, give me a call
703-305-3886
to go over case + 09/835370
will stop by
thanks
Jeff

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

****

STAFF USE ONLY	Type of Search		Vendors and cost where applicable	
Searcher:	NA Sequence (#)		STN	✓
Searcher Phone #: 4498	AA Sequence (#)		Dialog	
Searcher Location:	Structure (#)	✓	Questel/Orbit	
Date Searcher Picked Up: 4/22/03	Bibliographic	✓	Dr.Link	
Date Completed: 4/22/03	Litigation		Lexis/Nexis	
Searcher Prep & Review Time:	Fulltext		Sequence Systems	
Clerical Prep Time: 30	Patent Family		WWW/Internet	
Online Time: +45	Other		Other (specify)	

PTO-1590 (8-01)

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 12:00:37 ON 12 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)
```

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

```
Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 APR 2003  HIGHEST RN 502793-56-8
DICTIONARY FILE UPDATES:  11 APR 2003  HIGHEST RN 502793-56-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d sta que l13
L1              STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  37

STEREO ATTRIBUTES: NONE
L3              STR
```



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
L5 1080 SEA FILE=REGISTRY SSS FUL L3
L10 57 SEA FILE=REGISTRY SUB=L5 SSS FUL L1
L11 2 SEA FILE=REGISTRY ABB=ON PLU=ON L10 AND 6/NR
L13 1 SEA FILE=REGISTRY ABB=ON PLU=ON L11 NOT OC5-C6/ES

=> d ide can l13

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 189444-22-2 REGISTRY
CN Peptide nucleic acid, (H-C-C-A-T-T)-OH (9CI) (CA INDEX NAME)
FS NUCLEIC ACID SEQUENCE
MF C53 H69 N25 O17
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

PAGE 1-A



PAGE 2-A



PAGE 3-A



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 126:326433

=> d sta que l14
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE
L3 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
L5 1080 SEA FILE=REGISTRY SSS FUL L3
L10 57 SEA FILE=REGISTRY SUB=L5 SSS FUL L1
L12 2 SEA FILE=REGISTRY ABB=ON PLU=ON L10 AND 7/NR
L14 1 SEA FILE=REGISTRY ABB=ON PLU=ON L12 NOT 46.150.18/RID

=> d ide can l14

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 213272-49-2 REGISTRY
CN Peptide nucleic acid, (H-A-T-U-G-m5C)-OH (9CI) (CA INDEX NAME)
FS NUCLEIC ACID SEQUENCE
MF C54 H69 N27 O17
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 129:257138

=> d sta que l17
L3 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
L5 1080 SEA FILE=REGISTRY SSS FUL L3
L15 208 SEA FILE=REGISTRY ABB=ON PLU=ON L5 AND P/ELS
L16 122 SEA FILE=REGISTRY ABB=ON PLU=ON L15 AND 1/P
L17 4 SEA FILE=REGISTRY ABB=ON PLU=ON L16 AND 1/NR

=> d ide can tot l17

L17 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2003 ACS
RN 403517-90-8 REGISTRY
CN 8-Oxa-2,5-diaza-7-phosphadecanoic acid, 5-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-7-hydroxy-3-methyl-, 1,1-dimethylethyl ester, 7-oxide, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C18 H31 N4 O8 P**
SR CA
LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232515

L17 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2003 ACS
RN 403517-87-3 REGISTRY
CN 8-Oxa-2,5-diaza-7-phosphadecanoic acid, 5-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-7-ethoxy-3-methyl-, 1,1-dimethylethyl ester, 7-oxide, (3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C20 H35 N4 O8 P**
SR CA
LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:232515

L17 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2003 ACS
RN 329326-33-2 REGISTRY
CN Glycine, N-[2-(diethoxyphosphinyl)ethyl]-N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF **C15 H24 N3 O8 P**
SR CA
LC STN Files: CA, CAPLUS, CASREACT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:222969

L17 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2003 ACS
RN 183057-72-9 REGISTRY
CN Phosphonic acid, [[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl](2-hydroxyethyl)amino]methyl]-, diethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF **C14 H24 N3 O7 P**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 126:118140

REFERENCE 2: 126:100903

REFERENCE 3: 125:301493

=> d his

(FILE 'REGISTRY' ENTERED AT 11:48:48 ON 12 APR 2003)
DEL HIS
L1 STR
L2 STR
L3 STR L2
L4 50 S L3
L5 1080 S L3 FUL
SAV L5 SIEW835/A
L6 STR L2
L7 0 S L6 CSS SAM SUB=L5
L8 0 S L6 CSS FUL SUB=L5
SAV L8 SIEW835A/A
L9 1 S L1 SAM SUB=L5
L10 57 S L1 FUL SUB=L5
SAV L10 SIEW835B/A
L11 2 S L10 AND 6/NR
L12 2 S L10 AND 7/NR
L13 1 S L11 NOT OC5-C6/ES
L14 1 S L12 NOT 46.150.18/RID
L15 208 S L5 AND P/ELS
L16 122 S L15 AND 1/P
L17 4 S L16 AND 1/NR

FILE 'REGISTRY' ENTERED AT 12:00:37 ON 12 APR 2003

FILE 'HCAPLUS' ENTERED AT 12:01:57 ON 12 APR 2003
L18 7 S L13,L14,L17
L19 3 S L18 AND (UHLMANN ? OR BREIPOHL ? OR WILL D?)/AU
L20 3 S L18 AND HOECHST?/PA,CS
L21 3 S L19,L20
E US20020187473/PN
L22 1 S E3
SEL RN

```
     FILE 'REGISTRY' ENTERED AT 12:04:30 ON 12 APR 2003
L23           63 S E1-E63
L24            0 S L23 AND L5
L25            0 S L23 NOT SQL/FA
L26            2 S L23 NOT UNSPECIFIED
L27           61 S L23 NOT L26
L28           11 S L27 AND PEPTIDE
L29            5 S L28 AND 22/SQL
L30            6 S L28 NOT L29
L31            4 S L30 NOT ISOBENZOFURAN
L32            3 S L31 NOT THIENO
L33           50 S L27 NOT L28

     FILE 'HCAPLUS' ENTERED AT 12:14:20 ON 12 APR 2003
                E HID
                E UHLMANN E/AU
L34          179 S E3,E4,E14-E18
                E UEHLMANN E/AU
                E BRIEPOHL G/AU
                E BREIPOHL G/AU
L35          106 S E3-E6
                E BREIPOEHL G/AU
L36            1 S E2
                E WILL D/AU
L37           40 S E3,E7-E10
L38          275 S L34-L37
L39          274 S L38 NOT L22
                E PEPTIDE NUCLEIC ACID/CT
                E E4+ALL
L40         1717 S E3+NT
                E E2+ALL
L41         4496 S PEPTIDE(S)NUCLEIC ACID
L42         5022 S PNA
L43         8250 S L40-L42
L44        38606 S ?PEPTIDE?(S)(?NUCLEO? OR ?NUCLEI?)
L45        42349 S L43,L44
L46           37 S L38 AND L45
L47            7 S L18-L22 AND L45
L48            3 S L47 AND L38
L49            8 S L18-L22,L47,L48
L50           34 S L46 NOT L49

=> d 149 all hitstr tot

L49  ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2003 ACS
AN   2001:814939  HCAPLUS
DN   136:232515
TI   Synthesis of chiral phosphono-peptide nucleic
     acid monomers
AU   Wu, Yun; Xu, Jie-Cheng
CS   Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences,
     Shanghai, 200032, Peop. Rep. China
SO   Huaxue Xuebao (2001), 59(10), 1660-1666
     CODEN: HHHPA4; ISSN: 0567-7351
PB   Kexue Chubanshe
DT   Journal
LA   Chinese
CC   34-2 (Amino Acids, Peptides, and Proteins)
OS   CASREACT 136:232515
AB   Peptide nucleic acids are the potential
     candidate of antisense and antigene.  Chiral monomer backbones were
     efficiently prepd. by reductive amination of N-Boc or N-Fmoc protected
     L-alaninal with aminomethylphosphate di-Et ester and subsequent acylation
```

of free secondary amines with thymine-1-ylacetic acid. After chem. switch of N-Boc to N-Fmoc, protected chiral phosphono-**PNA** monomers were obtained.

ST amino phosphono nucleic acid prepn

IT Human
(synthesis of chiral **phosphonopeptide nucleic** acid monomers)

IT **Nucleic** acids
Peptide nucleic acids
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of chiral **phosphonopeptide nucleic acid** monomers)

IT 101-02-0, Triphenyl phosphite 621-84-1 15761-38-3 20924-05-4 28920-43-6 35661-39-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of chiral **phosphonopeptide nucleic** acid monomers)

IT 50917-72-1P 70908-61-1P 77393-49-8P 79069-50-4P 87694-49-3P 146803-41-0P 198542-03-9P 403517-85-1P 403517-86-2P **403517-87-3P** 403517-88-4P **403517-90-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of chiral **phosphonopeptide nucleic** acid monomers)

IT 76-05-1, Trifluoroacetic acid, reactions 109-02-4, N-Methylmorpholine 6638-79-5 13455-21-5, Potassium fluoride dihydrate 24608-52-4, tert-Butyl chloroformate 67126-19-6 403517-91-9
RL: RGT (Reagent); RACT (Reactant or reagent)
(synthesis of chiral **phosphonopeptide nucleic** acid monomers)

IT 403517-89-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of chiral **phosphonopeptide nucleic** acid monomers)

IT **403517-87-3P 403517-90-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of chiral **phosphonopeptide nucleic** acid monomers)

RN 403517-87-3 HCAPLUS

CN 8-Oxa-2,5-diaza-7-phosphadecanoic acid, 5-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-7-ethoxy-3-methyl-, 1,1-dimethylethyl ester, 7-oxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403517-90-8 HCAPLUS

CN 8-Oxa-2,5-diaza-7-phosphadecanoic acid, 5-[(3,4-dihydro-5-methyl-2,4-dioxo-

1(2H)-pyrimidinyl)acetyl]-7-hydroxy-3-methyl-, 1,1-dimethylethyl ester, 7-oxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Applicant

L49 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:780897 HCAPLUS
DN 135:331677
TI Methods for preparing phosphorylated **peptide nucleic acids** carrying one or more marker, crosslinking, intracellular uptake, or binding affinity groups
IN **Uhlmann, Eugen; Breipohl, Gerhard; Will, David William**
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DT Patent
LA German
IC ICM C07H
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 6, 33, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001079216	A2	20011025	WO 2001-EP4030	20010407
	WO 2001079216	A3	20020228		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 10019135	A1	20011031	DE 2000-10019135	20000418
	AU 2001054795	A5	20011030	AU 2001-54795	20010407
	EP 1276760	A2	20030122	EP 2001-927897	20010407
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001010110	A	20030211	BR 2001-10110	20010407
	US 2002187473	A1	20021212	US 2001-835371	20010417 <--
	NO 2002004959	A	20021015	NO 2002-4959	20021015
PRAI	DE 2000-10019135	A	20000418		
	WO 2001-EP4030	W	20010407		

OS MARPAT 135:331677
AB The invention relates to **PNA** derivs. that carry one or more phosphoryl groups at the C terminus or at the C and N terminus of the

PNA backbone, said phosphoryl groups optionally carrying one or more marker groups, or groups for crosslinking, or groups that promote the intracellular uptake, or groups that improve the binding affinity of the **PNA** deriv. to nucleic acids. The invention further relates to a method for producing the above **PNA** derivs. and to the use thereof as a medicament or diagnostic agent. Thus, title compd. CH3(CH2)15OP(O)(OH)-T(oeg)[ATTCCGTCAT](CH2)6NHP(O)(OH)O-CH2CH(CH2OH)(CH2)4NHC(S)NH-fluorescein (I) [T(oeg) = O(CH2)2N(C(O)CH2-Base)CH2C(O)-; remainder of chain = normal **peptide** **nucleic acid** backbone] was prepd. using solid-phase **peptide** synthesis techniques. Hybridization tests of I with complementary DNA and RNA showed better complexation with DNA than with RNA, though both were stronger than with **PNA** Ac-NH-TATTCCGTCAT-(CH2)6NH2 ref. In vitro cell proliferation studies using I and human pre-B leukemia cells showed stronger inhibition than a known phosphorothioate oligonucleotide (no data).

ST **PNA** deriv prepn antiviral antimicrobial antitumor diagnostic hybridization

IT Diagnosis
(agents; prepn. of **PNA** derivs. as therapeutic or diagnostic agents)

IT Solid phase synthesis
(peptide; prepn. of **PNA** derivs. as therapeutic or diagnostic agents)

IT Antimicrobial agents
Antitumor agents
Antiviral agents
Biosensors
Nucleic acid hybridization
(prepn. of **PNA** derivs. as therapeutic or diagnostic agents)

IT **Peptide nucleic acids**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of **PNA** derivs. as therapeutic or diagnostic agents)

IT 368505-39-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of **PNA** derivs. as therapeutic or diagnostic agents)

IT 367985-20-4P 367985-21-5P 367985-22-6P 367985-23-7P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of **PNA** derivs. as therapeutic or diagnostic agents)

IT 367985-17-9P 367985-19-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of **PNA** derivs. as therapeutic or diagnostic agents)

IT 367985-18-0P 368505-37-7P 368505-38-8P 368505-40-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of **PNA** derivs. as therapeutic or diagnostic agents)

IT 110616-00-7 116364-61-5 147178-75-4 159845-57-5 169025-57-4, GenBank AR029142 181988-02-3 181988-09-0 186070-79-1, GenBank A42375 186071-78-3 186108-31-6, 3: PN: WO0004034 SEQID: 3 unclaimed DNA 186123-93-3, GenBank A44395 186162-52-7 186162-55-0, GenBank A42368 189356-60-3 195184-07-7, GenBank A42342 195184-11-3, GenBank A42347 195184-12-4 195184-14-6, GenBank A42351 195184-15-7, GenBank A42352 195184-16-8, GenBank A44386 195184-17-9, GenBank A42354 195184-18-0, GenBank A42355 195184-19-1, GenBank A42356 195184-20-4, GenBank A42357 195184-21-5, GenBank A42358 195184-22-6, GenBank A42359 195184-23-7, GenBank A42361 195184-24-8, GenBank A42362 195184-25-9, GenBank A42363

195184-26-0, GenBank A47186 195184-27-1 195184-28-2, GenBank A47179
197831-18-8 246223-25-6 257601-47-1, GenBank AX283184 325605-36-5,
GenBank AX283169 325605-37-6, GenBank AX283174 325605-38-7
325605-39-8 325605-40-1 325605-41-2 325605-42-3 325605-43-4
325605-44-5 325605-45-6 325605-46-7 325605-47-8 325605-48-9
325605-49-0 325605-50-3 325605-51-4 325605-52-5
RL: PRP (Properties)
(unclaimed **nucleotide** sequence; methods for prepg.
phosphorylated **peptide nucleic acids**
carrying one or more marker, crosslinking, intracellular uptake, or
binding affinity groups)

L49 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2003 ACS
AN 2000:893130 HCAPLUS
DN 134:222969
TI Synthesis and characterization of a tetranucleotide analog containing alternating phosphonate-amide backbone linkages
AU Yu, P.; Wang, W.; Zhang, H.; Yang, X.; Liang, T. C.; Gao, X.
CS Department of Chemistry, University of Houston, Houston, TX, 77204-5641, USA
SO Bioorganic & Medicinal Chemistry (2001), 9(1), 107-119
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Science Ltd.
DT Journal
LA English
CC 33-10 (Carbohydrates)
Section cross-reference(s): 7, 34
OS CASREACT 134:222969
AB Described herein is the synthesis and characterization of a **tetranucleotide**, 5'-dC-phosphonate-T-amide-T-phosphonate-dC (III), in which the C-T and T-C steps contain a phosphonate backbone bond and T-T is a **peptide nucleic acid** dimer unit (neutral backbone). The 5'- and 3'-OH groups of the tetramer can be further derivatized and, thus, the compd. is a potential building block for longer oligonucleotides which will contain alternating backbone modifications at designated positions. The synthesis involved first the prepn. of two hybrid **peptide**-deoxyribose **dinucleotides**, CT-CO (I) and N-CT (II) (C and T are **nucleobases**; CO and N are carboxylic and amino terminal, resp.); each is linked through a phosphonate linkage. A condensation reaction between the two dimers, followed by deprotection, resulted in the formation of a peptide linkage to give the desired tetramer III. The reaction conditions used are mild to afford products in moderate to excellent yields. The DNA-**PNA**-DNA tetramer, d(CTTC), is a substrate for T4 kinase but fails to give a ligation product, even though NMR shows weak interactions between the tetramer III with its complementary sequence, d(GAAG).
ST **PNA** oligodeoxyribonucleotide phosphonate amide linkage synthesis substrate kinase
IT DNA
Peptide nucleic acids
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(synthesis and characterization of a **tetranucleotide** analog contg. alternating phosphonate-amide backbone linkages as enzyme substrates)
IT 501-53-1, Benzyl chloroformate 15715-58-9, Triethylammonium bicarbonate 128625-52-5
RL: RGT (Reagent); RACT (Reactant or reagent)
(prepn. of)
IT 9015-85-4, DNA ligase 37211-65-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(synthesis and characterization of a tetranucleotide analog contg. alternating phosphonate-amide backbone linkages as enzyme substrates)

IT 329326-31-0P
RL: BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(synthesis and characterization of a tetranucleotide analog contg. alternating phosphonate-amide backbone linkages as enzyme substrates)

IT 56-40-6, Glycine, reactions 107-15-3, Ethylenediamine, reactions 2094-72-6, 1-Adamantanecarbonyl chloride 2857-97-8, Bromotrimethylsilane 5324-30-1 20924-05-4 51549-36-1 51549-37-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and characterization of a tetranucleotide analog contg. alternating phosphonate-amide backbone linkages as enzyme substrates)

IT 144912-80-1P 144912-97-0P 210306-41-5P 329326-29-6P 329326-30-9P 329326-32-1P **329326-33-2P** 329326-34-3P 329326-35-4P 329326-36-5P 329326-37-6P 329326-38-7P 329326-39-8P 329326-40-1P 329326-41-2P 329326-42-3P 329326-43-4P 329326-44-5P 329326-45-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and characterization of a tetranucleotide analog contg. alternating phosphonate-amide backbone linkages as enzyme substrates)

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Agrawal, S; Curr Opin Biotechnol 1995, V6, P12 HCAPLUS
(2) Barawkar, D; J Am Chem Soc, published on web 2000
(3) Bergmann, F; Tetrahedron Lett 1995, V36, P6823 HCAPLUS
(4) Brown, S; Science 1994, V265, P777 HCAPLUS
(5) Crooke, S; Annu Rev Pharmacol Toxicol 1992, V32, P329 HCAPLUS
(6) Cross, C; Biochemistry 1997, V36, P4096 HCAPLUS
(7) De Mesmaeker, A; Angew Chem, Int Ed Engl 1994, V33, P226
(8) Ericksson, M; Quart Rev Biophys 1996, V29, P369
(9) Farese, A; Tetrahedron Lett 1996, V37, P1413 HCAPLUS
(10) Ferrer, E; Bioorg Med Chem 2000, V8, P291 HCAPLUS
(11) Gao, X; Biochemistry 1992, V31, P6228 HCAPLUS
(12) Gao, X; J Biomol NMR 1994, V4, P17 HCAPLUS
(13) Gao, X; J Biomol NMR 1994, V4, P367 HCAPLUS
(14) Gao, X; Nucleosides Nucleotides 1997, V16, P1599 HCAPLUS
(15) Imamura, M; Tetrahedron Lett 1996, V37, P1451 HCAPLUS
(16) Jones, R; J Org Chem 1993, V58, P2983 HCAPLUS
(17) Kosynkina, L; Tetrahedron Lett 1994, V35, P5173 HCAPLUS
(18) Kozlov, I; Bioconjug Chem 1998, V9, P415 HCAPLUS
(19) Leijon, M; Biochemistry 1994, V33, P9820 HCAPLUS
(20) Malchowski, W; J Org Chem 1994, V59, P7625
(21) Matteucci, M; Ciba Found Symp 1997, V209, P5 HCAPLUS
(22) Matteucci, M; Tetrahedron Lett 1990, V31, P2385 HCAPLUS
(23) McBride, L; Tetrahedron Lett 1983, V24, P245 HCAPLUS
(24) McBride, L; Tetrahedron Lett 1983, V24, P245 HCAPLUS
(25) McKenna, C; Tetrahedron Lett 1977, V18, P155
(26) Milligan, J; J Med Chem 1993, V36, P1923 HCAPLUS
(27) Morvan, F; J Am Chem Soc 1996, V118, P255 HCAPLUS
(28) Neilson, J; Tetrahedron Lett 1988, V29, P2911
(29) Nielsen, P; Chem Soc Rev 1997, P73 HCAPLUS
(30) Nielsen, P; Curr Opin Biotech 1999, V10, P71 HCAPLUS
(31) Nielsen, P; Science 1991, V254, P1497 HCAPLUS
(32) Peyman, A; Angew Chem, Int Ed Engl 1996, V35, P2636 HCAPLUS
(33) Rice, J; Biochemistry 1997, V36, P399 HCAPLUS
(34) Sanghvi, Y; Comprehensive Natural Products Chemistry 1998, V7
(35) Sczakiel, G; Front Biosci 2000, V5, PD194 HCAPLUS
(36) Stetsenko, D; Tetrahedron Lett 1996, V37, P3571 HCAPLUS
(37) Ti, G; J Am Chem Soc 1982, V104, P1316 HCAPLUS
(38) Uhlmann, E; Angew Chem Int Engl 1996, V35, P2632
(39) Uhlmann, E; Biol Chem 2000, V379, P1045

(40) Uhlmann, E; Chemical Reviews 1990, V90, P544
(41) Uhlmann, E; Methods Enzymol 2000, V313, P268 HCAPLUS
(42) van der Laan, A; Recl Trav Chim Pays-Bas 1995, V114, P295 HCAPLUS
(43) Vasseur, J; J Am Chem Soc 1992, V114, P4006 HCAPLUS
(44) Veal, J; J Am Chem Soc 1993, V115, P7139 HCAPLUS
(45) Wagner, R; Nature Biotech 1996, V14, P840 HCAPLUS
(46) Wang, W; Tetrahedron Lett 1995, V36, P1181 HCAPLUS
(47) Yang, X; Biochemistry 1999, V38, P12586 HCAPLUS
(48) Yang, X; J Biomol NMR 1997, V10, P383 HCAPLUS
(49) Zamecnik, P; Proc Natl Acad Sci USA 1978, V75, P280 HCAPLUS

IT **329326-33-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and characterization of a tetranucleotide analog contg. alternating phosphonate-amide backbone linkages as enzyme substrates)

RN 329326-33-2 HCAPLUS
CN Glycine, N-[2-(diethoxyphosphinyl)ethyl]-N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]- (9CI) (CA INDEX NAME)



L49 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:520988 HCAPLUS
DN 129:257138
TI Prediction of retention times of **peptide nucleic acids** during reversed-phase high-performance liquid chromatography
AU Hoffmann, Ralf; Bril, Gordon; Otvos, Laszlo
CS The Wistar Institute, Philadelphia, PA, 19104, USA
SO Journal of Chromatography, A (1998), 814(1 + 2), 111-119
CODEN: JCRAEY; ISSN: 0021-9673
PB Elsevier Science B.V.
DT Journal
LA English
CC 9-3 (Biochemical Methods)
Section cross-reference(s): 3

AB **Peptide nucleic acids** (**PNAs**) are synthetic biopolymers consisting of **nucleobase** side chains attached to an amino Et glycine backbone. At present this family of compds. enjoys a well deserved popularity in biomedical research, due to a no. of favorable biol. and chem. properties of **PNAs** compared to conventional synthetic oligonucleotides. **PNAs** are basically peptides, and are synthesized, purified and analyzed by traditional peptide chem., chromatog. and mass spectrometry techniques. In the current report, we analyzed factors that influence the elution behavior of 29 **PNAs** on reversed-phase high-performance liq. chromatog. using a water-acetonitrile-trifluoroacetic acid gradient elution system on C18 columns. We found that increasing the temp. from 25.degree. to 55.degree. resulted in improved peak shape and resoln. The retention times of the **PNA** analogs were dependent upon the length of the polymers with longer **PNAs** eluting later. Mixts. of **PNAs** with varying length, originating from inefficient monomer couplings during the polymer assembly, could be sepd. by single chromatog. runs. The retention time also depended upon the cytosine, thymine, adenine and guanine content of the polymers. These differences in the contribution to the retention

times could be explained by simple hydrophobicity features of the monomer side chains at pH 1.8. Based on all data, a linear equation was generated which predicted the retention time of any synthetic **PNA** based on compn. and length. Comparison of the predicted and obsd. retention times showed a remarkable reliability of the algorithm.

ST **peptide nucleic acid** reversed phase HPLC

IT Algorithm
Reversed phase HPLC
Temperature
(prediction of retention times of **peptide nucleic acids** during reversed-phase high-performance liq. chromatog.)

IT **Peptide nucleic acids**
RL: ANT (Analyte); PRP (Properties); ANST (Analytical study)
(prediction of retention times of **peptide nucleic acids** during reversed-phase high-performance liq. chromatog.)

IT 213272-46-9 213272-47-0 213272-48-1 **213272-49-2**
213272-50-5 213272-51-6 213272-52-7 213272-53-8 213272-54-9
213272-55-0 213272-56-1 213395-27-8 213395-29-0 213395-31-4
213395-33-6 213395-34-7 213395-36-9 213395-38-1 213395-40-5
213395-42-7 213395-43-8 213395-45-0 213395-46-1 213395-47-2
213395-48-3 213395-49-4 213395-50-7 213395-51-8 213395-52-9
RL: ANT (Analyte); ANST (Analytical study)
(prediction of retention times of **peptide nucleic acids** during reversed-phase high-performance liq. chromatog.)

IT 65-71-4, Thymine 71-30-7, Cytosine 73-24-5, Adenine, properties
73-40-5, Guanine
RL: PRP (Properties)
(prediction of retention times of **peptide nucleic acids** during reversed-phase high-performance liq. chromatog.)

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Boyes, B; Pept Res 1993, V3, P249
(2) Browne, C; Anal Biochem 1982, V124, P201 HCAPLUS
(3) Butler, J; Anal Chem 1996, V68, P3283 HCAPLUS
(4) Christensen, L; J Pept Sci 1995, V3, P175
(5) Cohen, K; Anal Biochem 1984, V140, P223 HCAPLUS
(6) Dueholm, K; J Org Chem 1994, V59, P5767 HCAPLUS
(7) Guo, D; J Chromatogr 1986, V359, P499 HCAPLUS
(8) Guo, D; J Chromatogr 1986, V359, P519 HCAPLUS
(9) Hamilton, S; Biochemistry 1997, V36, P11873 HCAPLUS
(10) Hearn, M; J Chromatogr 1978, V392, P33
(11) Hoffmann, R; Peptides:Chemistry, Structure and Biology, in press
(12) Hyrup, B; Bioorg Med Chem 1996, V4, P5 HCAPLUS
(13) Lowe, G; J Chem Soc Perkin Trans 1 1997, P555 HCAPLUS
(14) Mant, C; High-performance Liquid Chromatography of Peptides and Proteins:Separation, Analysis and Conformation 1991
(15) Meek, J; Proc Natl Acad Sci USA 1980, V77, P1632 HCAPLUS
(16) Nielsen, P; Science 1991, V254, P1497 HCAPLUS
(17) Norton, J; Bioorg Med Chem 1995, V3, P437 HCAPLUS
(18) Singhal, R; J Chromatogr 1988, V458, P117 HCAPLUS
(19) Sonveaux, E; Bioorg Chem 1986, V14, P274 HCAPLUS
(20) Stulik, K; Anal Chim Acta 1997, V352, P1 HCAPLUS
(21) Thomson, S; Tetrahedron 1995, V51, P6179 HCAPLUS
(22) van der Laan, A; Tetrahedron Lett 1997, V38, P2249 HCAPLUS

IT **213272-49-2**
RL: ANT (Analyte); ANST (Analytical study)
(prediction of retention times of **peptide nucleic acids** during reversed-phase high-performance liq. chromatog.)

RN 213272-49-2 HCAPLUS

CN Peptide nucleic acid, (H-A-T-U-G-m5C)-OH (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



L49 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:356548 HCAPLUS
DN 126:326433
TI a FISH method for detecting and quantifying multiple copies of a repeat sequence in a nucleic acid molecule in a single cell
IN Lansdorp, Peter
PA Lansdorp, Peter, Can.
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM G01N
CC 3-1 (Biochemical Genetics)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9714026	A2	19970417	WO 1996-CA676	19961010
	WO 9714026	A3	19970724		
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 870055	A2	19981014	EP 1996-932411	19961010
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6514693	B1	20030204	US 1996-730635	19961011
	US 2003022204	A1	20030130	US 2002-132002	20020425
PRAI	US 1995-5590P	P	19951012		
	US 1995-7616P	P	19951128		
	US 1996-730635	A	19961011		
	WO 1996-CA676	W	19961010		

AB A hybridization method for detecting or quantifying multiple copies of a repeat sequence in a nucleic acid mol. using a labeled hybridization probe is described. The method is preferably used for quantitating multiple copies of a repeat sequence in a nucleic acid mol., preferably a telomere or centromere repeat sequence. The preferred label is a fluorescent group and quantitation is by quant. fluorimtery. Novel probes for use in the method of the invention and kits are described. Using FITC-labeled

peptide nucleic acid probes, telomeres of
sister chromatids showed similar fluorescence, but fluorescence levels depended upon the chromosome. Fluorescence intensity also dropped with the no. of cell divisions that the cell had gone through.

ST repeat DNA detection quantitation; telomere repeat detection quantitation FISH

IT Chemiluminescence spectroscopy
(FISH method for detecting and quantifying multiple copies of repeat sequence in nucleic acid mol. in single cell)

IT Repetitive DNA
RL: ANT (Analyte); ANST (Analytical study)
(FISH method for detecting and quantifying multiple copies of repeat sequence in nucleic acid mol. in single cell)

IT Centromeres
Telomeres (chromosome)
(detection of repeat sequences at; FISH method for detecting and quantifying multiple copies of repeat sequence in nucleic acid mol. in single cell)

IT Nucleic acid hybridization
(in situ, fluorescence; FISH method for detecting and quantifying multiple copies of repeat sequence in nucleic acid mol. in single cell)

IT Nucleic acid hybridization
(in situ; FISH method for detecting and quantifying multiple copies of repeat sequence in nucleic acid mol. in single cell)

IT **Peptide nucleic acids**
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(labeled, hybridization probes for telomere repeat sequences; FISH method for detecting and quantifying multiple copies of repeat sequence in **nucleic acid** mol. in single cell)

IT Probes (nucleic acid)
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(labeled; FISH method for detecting and quantifying multiple copies of repeat sequence in nucleic acid mol. in single cell)

IT Fluorometry
(quant.; FISH method for detecting and quantifying multiple copies of repeat sequence in nucleic acid mol. in single cell)

IT 120178-12-3, Telomerase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(assay for ligands of, hybridization assay for telomere repeat DNA in; FISH method for detecting and quantifying multiple copies of repeat sequence in nucleic acid mol. in single cell)

IT 89802-96-0D, oligomers, conjugates with reporter moieties
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(hybridization probe for telomere repears; FISH method for detecting and quantifying multiple copies of repeat sequence in nucleic acid mol. in single cell)

IT 189444-15-3D, oligomers, conjugates 189444-16-4D, oligomers, conjugates 189444-17-5D, oligomers, conjugates 189444-18-6D, oligomers, conjugates 189444-19-7D, oligomers, conjugates 189444-20-0D, oligomers, conjugates 189444-21-1D, oligomers, conjugates **189444-22-2D**, oligomers, conjugates 189444-23-3D, oligomers, conjugates 189444-24-4D, oligomers, conjugates 189520-39-6D, oligomers, conjugates 189520-40-9D, oligomers, conjugates
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
(hybridization probe; FISH method for detecting and quantifying multiple copies of repeat sequence in nucleic acid mol. in single cell)

IT 117490-04-7
RL: ANT (Analyte); ANST (Analytical study)
(telomere repeat sequence, detection and quantification of; FISH method for detecting and quantifying multiple copies of repeat sequence in nucleic acid mol. in single cell)

IT **189444-22-2D**, oligomers, conjugates

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
(hybridization probe; FISH method for detecting and quantifying multiple copies of repeat sequence in nucleic acid mol. in single cell)

RN 189444-22-2 HCAPLUS

CN Peptide nucleic acid, (H-C-C-A-T-T)-OH (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A



L49 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:88503 HCAPLUS
DN 126:100903
TI Phosphonomonoester nucleic acids, process for their preparation, and their use in molecular biology and as pharmaceuticals
IN Peyman, Anuschirwan; **Uhlmann, Eugen; Breipohl, Gerhard** ; Wallmeier, Holger
PA **Hoechst A.-G., Germany**
SO Can. Pat. Appl., 126 pp.
CODEN: CPXXEB
DT Patent
LA English
IC ICM C12Q001-68
ICS C07K002-00; C07H021-00; A61K048-00; A61K031-70; A61K038-00
CC 6-2 (General Biochemistry)
Section cross-reference(s): 1, 3, 33
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2171589	AA	19960914	CA 1996-2171589	19960312
	DE 19508923	A1	19960919	DE 1995-19508923	19950313

DE 19543865 A1 19970605 DE 1995-19543865 19951124
PRAI DE 1995-19508923 A 19950313
DE 1995-19543865 A 19951124
OS CASREACT 126:100903
AB Novel **oligonucleotide** analogs which may be loosely described as phosphonomonoester analogs of **peptide nucleic acids** (PMENA's) and methods for their synthesis are claimed. Particularly preferred PMENA analogs are Q-[OP(:O)(OR)CH2N(COCH2B)CH2CH2]n O-Q' (n=1-25; R=OH, OEt, OPh, etc.; B=natural nucleobase; Q,Q'=H, alkyl, Ph, etc. or an oligonucleotide or modified oligonucleotide). Their application relates to use as inhibitors of gene expression (antisense oligonucleotides, ribozymes, sense oligonucleotides and triplex-forming oligonucleotides), as probes for the detection of nucleic acids and as auxiliaries in mol. biol. PMENA analog H-[OP(:O)(OH)CH2N(COCH2T)CH2CH2]9O P(:O)(OEt)OEt was prepd. and its interaction with (dA)9 examd. by UV spectroscopy and by gel shift anal. The Tm for the PMENA analog-(dA)9 complex was 23.degree..
ST oligonucleotide analog phosphonomonoester synthesis pharmaceutical
IT Oligonucleotides
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(analogs; phosphonomonoester nucleic acids prepn. and use in mol. biol. and as pharmaceuticals)
IT Artery, disease
(coronary, restenosis, prevention of; phosphonomonoester nucleic acids prepn. and use in mol. biol. and as pharmaceuticals)
IT Gene
(expression, inhibition of; phosphonomonoester nucleic acids prepn. and use in mol. biol. and as pharmaceuticals)
IT Antitumor agents
Antiviral agents
(phosphonomonoester nucleic acids prepn. and use in mol. biol. and as pharmaceuticals)
IT Probes (nucleic acid)
RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
(phosphonomonoester nucleic acids prepn. and use in mol. biol. and as pharmaceuticals)
IT Growth factors, animal
Tumor necrosis factors
RL: MSC (Miscellaneous)
(treatment of diseases involving; phosphonomonoester nucleic acids prepn. and use in mol. biol. and as pharmaceuticals)
IT Hepatitis B virus
Human herpesvirus 1
Human herpesvirus 2
Human immunodeficiency virus
Influenza virus
Papillomavirus
(treatment of infection by; phosphonomonoester nucleic acids prepn. and use in mol. biol. and as pharmaceuticals)
IT 185670-74-0P
RL: PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(phosphonomonoester nucleic acids prepn. and use in mol. biol. and as pharmaceuticals)
IT 50-00-0, Formaldehyde, reactions 100-27-6 107-18-6, 2-Propen-1-ol, reactions 141-43-5, reactions 762-04-9 4712-55-4 14470-28-1 20924-05-4 57260-73-8 78635-98-0 89992-70-1 102774-86-7 172405-10-6 172405-18-4 172405-25-3 185670-94-4
RL: RCT (Reactant); RACT (Reactant or reagent)

(phosphonomonoester nucleic acids prepn. and use in mol. biol. and as pharmaceuticals)

IT 85363-76-4P 105496-31-9P 183057-32-1P 183057-37-6P 183057-48-9P
183057-51-4P 183057-55-8P 183057-59-2P 183057-63-8P 183057-66-1P
183057-69-4P **183057-72-9P** 183057-75-2P 183057-79-6P
183057-82-1P 183057-84-3P 183057-88-7P 183057-91-2P 183057-94-5P
183057-96-7P 183057-99-0P 183058-02-8P 183058-04-0P 183058-06-2P
183058-09-5P 183058-10-8P 183058-11-9P 183058-12-0P 183058-13-1P
183058-14-2P 183058-15-3P 183058-16-4P 183058-18-6P 183058-19-7P
183058-21-1P 183058-22-2P 183058-25-5P 185670-36-4P 185670-58-0P
185670-59-1P 185670-60-4P 185670-61-5P 185670-62-6P 185670-63-7P
185670-64-8P 185670-65-9P 185670-66-0P 185670-67-1P 185670-68-2P
185670-69-3P 185670-70-6P 185670-71-7P 185670-72-8P 185670-76-2P
185670-78-4P 185670-79-5P 185670-80-8P 185670-81-9P 185670-82-0P
185670-84-2P 185670-87-5P 185670-90-0P 185670-92-2P 185670-95-5P
185670-96-6P 185670-97-7P 185670-98-8P 185670-99-9P 185671-00-5P
185671-01-6P 185671-02-7P 185671-03-8P 185830-87-9P 185830-88-0P
185830-89-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(phosphonomonoester nucleic acids prepn. and use in mol. biol. and as pharmaceuticals)

IT **183057-72-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(phosphonomonoester nucleic acids prepn. and use in mol. biol. and as pharmaceuticals)

RN 183057-72-9 HCAPLUS

CN Phosphonic acid, [[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl](2-hydroxyethyl)amino]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



L49 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 1996:755989 HCAPLUS

DN 126:118140

TI Phosphonic ester nucleic acids (PHONAs): oligodeoxyribonucleotide analog with an achiral phosphonic acid ester backbone

AU Peyman, Anusch; **Uhlmann, Eugen**; Wagner, Konrad; Augustin, Sascha; **Breipohl, Gerhard**; **Will, David W.**; Schaefer, Andrea; Wallmeier, Holger

CS **Hoechst AG, Frankfurt, D-65926, Germany**

SO Angewandte Chemie, International Edition in English (1996), 35(22), 2636-2638
CODEN: ACIEAY; ISSN: 0570-0833

PB VCH

DT Journal

LA English

CC 33-9 (Carbohydrates)

Section cross-reference(s): 6

AB The prepn. of polyamide nucleic acid analogs with an achiral and neg. charged backbone to which the nucleobases are attached through carboxymethylene linkers, is reported.

ST oligodeoxyribonucleotide phosphonic ester duplex prepn; PHONA nucleic acid duplex prepn; phosphonic ester nucleic acid duplex prepn; polyamide nucleic acid analog duplex prepn

IT Nucleic acids
Oligodeoxyribonucleotides
RL: SPN (Synthetic preparation); PREP (Preparation)
(phosphonic ester, PHONAs; prepn. of phosphonic ester nucleic acid duplexes)

IT 20924-05-4 77451-51-5 183057-37-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of phosphonic ester nucleic acid duplexes)

IT 85363-76-4P 183057-48-9P 183057-69-4P **183057-72-9P**
183057-84-3P 183057-87-6P 183058-02-8P 183058-04-0P 183058-10-8P
183058-22-2P 185670-36-4P 185670-58-0P 185670-59-1P 185670-60-4P
185670-64-8P 185670-74-0P 185830-87-9P 186143-34-0P 186143-35-1P
186143-36-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of phosphonic ester nucleic acid duplexes)

IT 186272-60-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of phosphonic ester nucleic acid duplexes)

IT **183057-72-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of phosphonic ester nucleic acid duplexes)

RN 183057-72-9 HCAPLUS

CN Phosphonic acid, [[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl](2-hydroxyethyl)amino]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



L49 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2003 ACS

AN 1996:672510 HCAPLUS

DN 125:301493

TI Preparation of nucleic acid phosphonoesters as inhibitors of gene expression.

IN Anuschirwan, Peyman; **Uhlmann, Eugen; Breipohl, Gerhard**; Wallmeier, Holger

PA **Hoechst A.-G., Germany**

SO Ger. Offen., 36 pp.
CODEN: GWXXBX

DT Patent

LA German

IC ICM C07H021-00

ICS C07H001-00; C07F009-6506; A61K031-70
ICA C07F009-38; C07F009-6561; C12N007-06
CC 33-9 (Carbohydrates)
Section cross-reference(s): 1, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19508923	A1	19960919	DE 1995-19508923	19950313
	EP 739898	A2	19961030	EP 1996-103533	19960307
	EP 739898	A3	19980916		
	EP 739898	B1	20010926		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AT 206131	E	20011015	AT 1996-103533	19960307
	ES 2165446	T3	20020316	ES 1996-103533	19960307
	US 5874553	A	19990223	US 1996-613417	19960311
	CA 2171589	AA	19960914	CA 1996-2171589	19960312
	NO 9601006	A	19960916	NO 1996-1006	19960312
	AU 9648028	A1	19960926	AU 1996-48028	19960312
	AU 706470	B2	19990617		
	ZA 9601986	A	19961121	ZA 1996-1986	19960312
	BR 9600993	A	19971230	BR 1996-993	19960312
	JP 08259579	A2	19961008	JP 1996-84808	19960313
	CN 1138588	A	19961225	CN 1996-100508	19960313
	CN 1060781	B	20010117		
	US 6127346	A	20001003	US 1998-196132	19981120
PRAI	DE 1995-19508923	A	19950313		
	DE 1995-19543865	A	19951124		
	US 1996-613417	A1	19960311		

AB QXP(Z)(:Y)CR5R6L(AB)DGX[P(Z)(:Y)CR5R6L(AB)DGX]nQ1 [n = 0-100; B = H, OH, alkoxy, alkylthio, (un)natural **nucleobase**, reporter ligand, (substituted) alkyl, aryl, aralkyl, heterocyclyl, etc.; AB = amino acid or **peptide** residue; R1 = H, (substituted) alkyl; R5, R6 = H, (substituted) alkyl, aryl, aralkyl, OH, alkoxy, alkylthio; A = bond, CH2, (O-, S-, or NR1-interrupted) (substituted) alkylene; D, G = (substituted) methylene; X, Y = O, S, NR1; Z = OH, alkoxy, alkenyloxy, alkynyloxy, amino, etc.; Q, Q1 = H, conjugate, (modified) **oligonucleotide**], were prepd. as drugs and diagnostic agents (no data). Thus, N-(4-methoxytriphenylmethoxy)ethylaminomethanephosphonic acid di[2-(p-nitrophenyl)ethyl]ester (prepn. given) was stirred with N-ethylmorpholine, HATU, and N6-anisoylcytosine-1-acetic acid in DMF to give a coupling product which was stirred with DBU in MeCN to give N-(N6-anisoylcytosin-1-ylacetyl)-N-(4-methoxytriphenylmethoxy)ethylaminomethanephosphonic acid [2-(p-nitrophenyl)ethyl] monoester.

ST nucleic acid phosphonoester gene expression inhibitor; diagnostic agent nucleic acid phosphonoester; anticancer nucleic acid phosphonoester prepn; restenosis treatment nucleic acid phosphonoester; antiviral nucleic acid phosphonoester

IT Nucleic acids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(esters; prepn. of nucleic acid phosphonoesters as inhibitors of gene expression)

IT Neoplasm inhibitors
Virucides and Virustats
(prepn. of nucleic acid phosphonoesters as inhibitors of gene expression)

IT Integrins
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(treatment of integrin-influenced disease; prepn. of nucleic acid phosphonoesters as inhibitors of gene expression)

IT Diagnosis

(agents, prepn. of nucleic acid phosphonoesters as inhibitors of gene expression)

IT Adhesion
(bio-, treatment of cell-cell adhesion-influenced disease; prepn. of nucleic acid phosphonoesters as inhibitors of gene expression)

IT Heart, disease
(restenosis, treatment; prepn. of nucleic acid phosphonoesters as inhibitors of gene expression)

IT Lymphokines and Cytokines
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(tumor necrosis factor, treatment of TNF-influenced disease; prepn. of nucleic acid phosphonoesters as inhibitors of gene expression)

IT 183057-48-9P 183057-51-4P 183057-55-8P 183057-63-8P 183057-66-1P
183057-69-4P **183057-72-9P** 183057-75-2P 183057-79-6P
183057-82-1P 183057-84-3P 183057-94-5P 183058-02-8P 183058-06-2P
183058-10-8P 183058-11-9P 183058-12-0P 183058-14-2P 183058-19-7P
183058-22-2P 183058-25-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of nucleic acid phosphonoesters as inhibitors of gene expression)

IT 183057-59-2P 183057-88-7P 183057-91-2P 183057-96-7P 183057-99-0P
183058-04-0P 183058-09-5P 183058-13-1P 183058-15-3P 183058-16-4P
183058-18-6P 183058-21-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nucleic acid phosphonoesters as inhibitors of gene expression)

IT 100-27-6 107-18-6, Allyl alcohol, reactions 141-43-5, 2-Aminoethanol, reactions 762-04-9, Diethyl phosphite 1129-37-9, p-Nitrobenzaldoxime 4712-55-4, Diphenyl phosphite 20924-05-4 172405-10-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of nucleic acid phosphonoesters as inhibitors of gene expression)

IT 85363-76-4P 105496-31-9P 183057-32-1P 183057-37-6P 183057-42-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of nucleic acid phosphonoesters as inhibitors of gene expression)

IT **183057-72-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of nucleic acid phosphonoesters as inhibitors of gene expression)

RN 183057-72-9 HCAPLUS

CN Phosphonic acid, [[[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl](2-hydroxyethyl)amino]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



=> d l50 bib abs retable tot

L50 ANSWER 1 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:805617 HCAPLUS
TI (2'-O-methyl-RNA)-3'-**PNA** chimeras: A new class of mixed backbone oligonucleotide analogues with high binding affinity to RNA
AU Greiner, Beate; **Breipohl, Gerhard**; **Uhlmann, Eugen**
CS Aventis Pharma Deutschland GmbH, Frankfurt a.M., D-65926, Germany
SO Helvetica Chimica Acta (2002), 85(9), 2619-2626
CODEN: HCACAV; ISSN: 0018-019X
PB Verlag Helvetica Chimica Acta
DT Journal
LA English
AB The automated online synthesis of DNA-3'-**PNA** chimeras 1-4 and (2'-O-methyl-RNA)-3'-**PNA** chimeras 5-8 is described, in which the 3'-terminal part of the oligonucleotide is linked to the N-terminal part of the **PNA** via N-(.omega.-hydroxyalkyl)-N-[(thymin-1-yl)acetyl]glycine units (alkyl=Et, Ph, Bu, and pentyl). By means of UV thermal denaturation, the binding affinities of all chimeras were directly compared by detg. their Tm values in the duplex with complementary DNA and RNA. All investigated DNA-3'-**PNA** chimeras and (2'-O-methyl-RNA)-3'-**PNA** chimeras form more-stable duplexes with complementary DNA and RNA than the corresponding unmodified DNA. Interestingly, a N-(3-hydroxypropyl)glycine linker resulted in the highest binding affinity for DNA-3'-**PNA** chimeras, whereas the (2'-O-methyl-RNA)-3'-**PNA** chimeras showed optimal binding with the homologous N-(4-hydroxybutyl)glycine linker. The duplexes of (2'-O-methyl-RNA)-3'-**PNA** chimeras and RNA were significantly more stable than those contg. the corresponding DNA-3'-**PNA** chimeras. Surprisingly, we found that the charged (2'-O-methyl-RNA)-3'-**PNA** chimera with a N-(4-hydroxybutyl)glycine-based unit at the junction to the **PNA** part shows the same binding affinity to RNA as uncharged **PNA**. Potential applications of (2'-O-methyl-RNA)-3'-**PNA** chimeras include their use as antisense agents acting by a RNase-independent mechanism of action, a prerequisite for antisense-oligonucleotide-mediated correction of aberrant splicing of pre-mRNA.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Breipohl, G	1997	53	14671	Tetrahedron	
Breipohl, G	1996		61	` Innovation and Per	HCAPLUS
Freier, S	1997	25	4429	Nucleic Acids Res	HCAPLUS
Greiner, B	1999	82	2151	Helv Chim Acta	HCAPLUS
Matteucci, M	1981	103	3185	J Am Chem Soc	HCAPLUS
Nielsen, P	1997	26	73	Chem Soc Rev	HCAPLUS

Nielsen, P	1991	254	1497	Science	HCAPLUS
Uhlmann, E	1996	35	2632	Angew Chem, Int Ed	
Uhlmann, E	1998	37	2796	Angew Chem, Int Ed	HCAPLUS
Uhlmann, E	1998	379	1045	Biol Chem	HCAPLUS
Uhlmann, E	2000	3	203	Curr Opin Drug Disco	HCAPLUS
Uhlmann, E	1999		51	` Peptide Nucleic Ac	HCAPLUS
van der Laan, A	1998	8	663	Bioorg Med Chem Lett	HCAPLUS
Will, D	1995	51	12069	Tetrahedron	HCAPLUS

L50 ANSWER 2 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:780930 HCAPLUS
DN 135:331678
TI Methods for preparing phosphorylated **peptide nucleic acids** carrying one or more marker, crosslinking, intracellular uptake, or binding affinity groups
IN **Uhlmann, Eugen; Breipohl, Gerhard; Will, David William**
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001079249	A2	20011025	WO 2001-EP4027	20010407
	WO 2001079249	A3	20020328		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 10019136	A1	20011031	DE 2000-10019136	20000418
	BR 2001010111	A	20030211	BR 2001-10111	20010407
	EP 1282639	A2	20030212	EP 2001-919443	20010407
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003022172	A1	20030130	US 2001-835370	20010417
	NO 2002004960	A	20021112	NO 2002-4960	20021015
PRAI	DE 2000-10019136	A	20000418		
	WO 2001-EP4027	W	20010407		

AB The invention relates to **PNA** derivs. which carry a phosphoryl radical on the N terminus of the **PNA** backbone, for example a phosphate or a substituted phosphoryl radical, substituted phosphoryl derives optionally carrying one or more marker groups or groups for crosslinking or groups which favor intracellular take-up or groups which increase the binding affinity of the **PNA** deriv. to nucleic acids. The invention also relates to a method for producing the aforementioned **PNA** derivs. and to their use as medicaments and diagnostic agents. Thus, several **PNA** chains were prepd.using solid phase peptide synthesis techniques, in which the C-terminal was capped by NH(CH2)6OH and the N-terminal H2N- group was replaced by HO-, and functionalized to H2O3PO- or ROP(O)(OH)O- (R = biotin or fluorescein tag group or alkyl cap). Hybridization tests with complementary DNA or RNA showed increased binding, compared to a normal **PNA** chain N-capped with H3CC(O)- and C-capped with NH(CH2)6OH. In vitro cellular uptake studies were done with fluorescein-tagged **PNA** (no data). In vitro cell proliferation studies were done with a H3C(CH2)15OP(O)(OH)-capped **PNA** using human pre-B leukemia cells or A549-tumor cells

(no data).

L50 ANSWER 3 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:197663 HCAPLUS
TI Recent progress in the synthesis and cellular uptake of modified oligonucleotides
AU **Uhlmann, Eugen**
CS Medicinal Chemistry, Aventis Pharma Deutschland GmbH, Frankfurt a. M, 65926, Germany
SO Abstracts of Papers - American Chemical Society (2001), 221st, CARB-010
CODEN: ACSRAL; ISSN: 0065-7727
PB American Chemical Society
DT Journal; Meeting Abstract
LA English
AB The biol. efficacy of antisense oligonucleotides depends strongly on their cellular uptake and intracellular distribution. In order to improve the uptake characteristics of **oligonucleotides**, several routes have been investigated by us in recent years, including the incorporation of certain **nucleotide** sequence motifs, the covalent attachment of carrier **peptides**, the replacement of the neg. charged phosphodiester linkage by uncharged structural elements, and the conjugation of lipophilic or ionophoric moieties to the oligomers. Depending on the type of modification, other parameters, such as binding affinity, nuclease stability, and the capability of inducing RNase H, were also found to be altered. An overview of various synthetic strategies for the modification of oligonucleotides as well as their impact on the biophys. and biol. properties will be presented.

L50 ANSWER 4 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 2000:258582 HCAPLUS
DN 133:89771
TI Olefinic **peptide nucleic acids** (OPAs): new aspects of the molecular recognition of DNA by **PNA**
AU Schutz, Rolf; Cantin, Michel; Roberts, Christopher; Greiner, Beate; **Uhlmann, Eugen**; Leumann, Christian
CS Department of Chemistry and Biochemistry, University of Bern, Bern, 3012, Switz.
SO Angewandte Chemie, International Edition (2000), 39(7), 1250-1253
CODEN: ACIEF5; ISSN: 1433-7851
PB Wiley-VCH Verlag GmbH
DT Journal
LA English
GI



I

AB In order to study the structural and electrostatic effect of the **PNA** rotameric forms, the authors have synthesized olefinic polyamide nucleic acids (OPAs) in which the central amide functionality was replaced by an isostructural, configurationally stable C-C double bond in either the Z or E configuration (I; BASE = thymidine or adenine), and

used them to prep. (E)- or (Z)-OPA oligomers. A series of mono-substituted **PNAs** and fully-modified (E) and (Z)-OPAs were synthesized and their duplex-forming behavior with DNA studied. Both (E)- and (Z)-OPAs bound to complementary DNA with similar affinities as DNA itself, but in contrast to **PNA**, OPA2/DNA triplexes were not formed, and OPA preferentially bound in the parallel mode to DNA. Results led to the conclusion that amide functionality in the base-linked unit in **PNA** detd. significantly the affinity and preferred strand orientation in **PNA**/DNA duplexes, and seemed to be responsible for the propensity to form PNA2/DNA triplexes; these properties do not depend on the conformational constraints that the amide functionality exerts on the base-linker unit, but rather on its electrostatic properties.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Almarsson, O	1993	90	7518	Proc Natl Acad Sci U	HCAPLUS
Almarsson, O	1993	90	9542	Proc Natl Acad Sci U	HCAPLUS
Anon	1999			Peptide Nucleic Acid	
Bannwarth, W	1988	71	1517	Helv Chim Acta	HCAPLUS
Betts, L	1995	270	1838	Science	HCAPLUS
Brown, S	1994	265	777	Science	HCAPLUS
Cantin, M	1997	38	4211	Tetrahedron Lett	HCAPLUS
Egholm, M	1993	365	566	Nature	HCAPLUS
Hyrup, B	1996	6	1083	Bioorg Med Chem Lett	HCAPLUS
Hyrup, B	1994	116	7964	J Am Chem Soc	HCAPLUS
Leijon, M	1994	33	9820	Biochemistry	HCAPLUS
Nielsen, P	1997	26	73	Chem Soc Rev	HCAPLUS
Nielsen, P	1993	23	323	Origins Life Evol Bi	HCAPLUS
Nielsen, P	1991	254	1497	Science	HCAPLUS
Rasmussen, H	1997	4	98	Nat Struct Biol	HCAPLUS
Roberts, C	1999		819	Synlett	HCAPLUS
Uhlmann, E	1996	108	2793	Angew Chem	
Uhlmann, E	1998	110	2954	Angew Chem	
Uhlmann, E	1998	37	2796	Angew Chem Int Ed	HCAPLUS
Uhlmann, E	1996	35	2632	Angew Chem Int Ed En	
Uhlmann, E	1998	32	150	Chemie Unserer Zeit	HCAPLUS
Will, D	1995	51	12069	Tetrahedron	HCAPLUS

L50 ANSWER 5 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 2000:41751 HCAPLUS
DN 132:304723
TI Influence of the type of junction in DNA-3'-**peptide nucleic acid** (**PNA**) chimeras on their binding affinity to DNA and RNA
AU Greiner, Beate; **Breipohl, Gerhard; Uhlmann, Eugen**
CS Hoechst Marion Roussel Deutschland GmbH, Chemical Research G 838, Frankfurt, D-65926, Germany
SO Helvetica Chimica Acta (1999), 82(12), 2151-2159
CODEN: HCACAV; ISSN: 0018-019X
PB Verlag Helvetica Chimica Acta
DT Journal
LA English
AB The automated online synthesis of a series of three DNA-3'-**PNA** (**PNA** = Polyamide Nucleic Acids) chimeras is described, in which the 3'-terminus of the oligonucleotide is linked to the amino terminus of the **PNA** via an N-(2-mercaptoethyl)- (X=S), N-(2-hydroxyethyl)- (X=O), or N-(2-aminoethyl)- (X=NH) N-[(thymin-1-yl)acetyl]glycine unit. In addn., the DNA-3'-**PNA** chimera with no nucleobase at the linking unit was prepd. The binding affinities of all chimeras were directly compared by detg. their Tm values in duplexes with complementary DNA, RNA, or DNA contg. a mismatch or abasic site opposite to the linker unit. We

found that all chimeras in this study which have a nucleobase at the junction were able to form more stable duplexes with complementary DNA and RNA than the corresponding unmodified DNA. The influence of X on duplex stabilization was detd. to be O > S .apprxeq. NH, thus demonstrating the phosphodiester bridge to be the most favored linkage at the DNA/**PNA** junction. The strong duplex-destabilizing effects obsd. when base mismatches or non-basic sites were introduced opposite the nucleobase at the DNA/**PNA** junction, suggest that the base situated at the linking unit contributes significantly to duplex stabilization.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bergmann, F	1995	36	6823	Tetrahedron Lett	HCAPLUS
Breipohl, G	1997	53	14671	Tetrahedron	
Egholm, M	1993	365	566	Nature	HCAPLUS
Hyrup, B	1996	4	5	Bioorg Med Chem	HCAPLUS
Matteucci, M	1981	103	3185	J Am Chem Soc	HCAPLUS
Nielsen, P	1991	254	1497	Science	HCAPLUS
Petersen, K	1995	5	1119	Bioorg Med Chem Lett	HCAPLUS
Uhlmann, E	1996	35	2632	Angew Chem, Int Ed	
Uhlmann, E	1998	37	2796	Angew Chem, Int Ed	HCAPLUS
Uhlmann, E	1998	379	1045	Biol Chem	HCAPLUS
Uhlmann, E	1999		51	Peptide Nucleic Acid	HCAPLUS
van der Laan, A	1998	8	663	Bioorg Med Chem Lett	HCAPLUS
Will, D	1995	51	12069	Tetrahedron	HCAPLUS

L50 ANSWER 6 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:501533 HCAPLUS
DN 132:194633
TI **PNA**/DNA chimeras
AU **Uhlmann, Eugen**; Greiner, Beate; **Breipohl, Gerhard**
CS Hoechst Marion Roussel Deutschland GmbH Chemical Research G 838, Frankfurt am Main, D-65926, Germany
SO Peptide Nucleic Acids (1999), 51-70. Editor(s): Nielsen, Peter E.; Egholm, Michael. Publisher: Horizon Scientific Press, Norfolk, UK. CODEN: 67YLA6
DT Conference
LA English
AB A convenient method for the solid-support synthesis of **PNA**/DNA chimeras is described which makes use of monomethoxytrityl/acyl-protected monomeric building blocks. The acid-labile monomethoxytrityl (Mmt) group is employed for the temporary protection of the amino function of aminoethyl-glycine, while the exocyclic amino functions of the nucleobases are protected with ammonia-cleavable acyl protecting groups. This orthogonal protecting-group strategy is fully compatible with the std. phosphoramidite DNA synthesis method. The resulting **PNA**/DNA chimeras obey the Watson-Crick rules on binding to complementary DNA and RNA. Binding affinity of the **PNA**-DNA chimeras strongly depends on the **PNA**:DNA ratio. The **PNA**/DNA chimeras bind with higher affinity to RNA than to DNA, and the type of linking moiety between **PNA** and DNA could be adjusted to obtain optimal binding affinity. In addn. to their promising binding properties, **PNA**-DNA chimeras can also assume biol. functions, such as a primer function for DNA polymerases. Pure **PNAs** cannot induce RNase H cleavage of target RNA, which often supports the biol. efficacy of antisense agents. In contrast, the DNA-**PNA** chimeras are able to stimulate cleavage of the target RNA by RNase H on formation of a RNA chimera duplex.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bannwarth, W	1988	71	1517	Helv Chim Acta	HCAPLUS

Bergmann, F	1995	36	6823	Tetrahedron Lett	HCAPLUS
Betts, L	1995	270	1838	Science	HCAPLUS
Bonham, M	1995	23	1197	Nucleic Acids Res	HCAPLUS
Breipohl, G	1999			In preparation	
Breipohl, G	1996		61	Innovation and Persp	HCAPLUS
Breipohl, G	1997	53	14671	Tetrahedron	
Christensen, L	1995	1	175	J Pept Sci	MEDLINE
Egholm, M	1993	365	566	Nature	HCAPLUS
Egholm, M	1995	23	217	Nucleic Acids Res	HCAPLUS
Finn, P	1996	24	3357	Nucleic Acids Res	HCAPLUS
Hyrup, B	1996	4	5	Bioorg Med Chem	HCAPLUS
Koppelhus, U	1997	25	2167	Nucleic Acids Res	HCAPLUS
Lutz, M	1997	119	3177	J Am Chem Soc	HCAPLUS
Mag, M	1989	17	5973	Nucleic Acids Res	HCAPLUS
Matteucci, M	1981	103	3185	J Am Chem Soc	HCAPLUS
Nielsen, P	1993	8	53	Anti-Cancer Drug Des	HCAPLUS
Nielsen, P	1991	254	1497	Science	HCAPLUS
Petersen, K	1995	5	1119	Bioorg Med Chem Lett	HCAPLUS
Peyman, A	1996	35	2636	Angew Chem Int Ed	HCAPLUS
Peyman, A	1998	36	2809	Angew Chem Int Ed	
Peyman, A		17	1997	Nucleosides Nucleoti	HCAPLUS
Stetsenko, D	1996	37	3571	Tetrahedron Lett	HCAPLUS
Thomson, S	1995	51	6179	Tetrahedron	HCAPLUS
Torrence, P	1993	90	1300	Proc Natl Acad Sci	HCAPLUS
Uhlmann, E	1996	35	2632	Angew Chem Int Ed	
Uhlmann, E	1998	37	2796	Angew Chem Int Ed	HCAPLUS
Uhlmann, E	1998	379	1045	Biol Chem	HCAPLUS
Uhlmann, E	1990	90	543	Chem Rev	HCAPLUS
Uhlmann, E	1997		64	Encyclopedia of Canc	
Uhlmann, E	1997	16	603	Nucleosides Nucleoti	HCAPLUS
van der Laan, A	1998	8	663	Bioorg Med Chem Lett	HCAPLUS
van der Laan, A	1995	114	295	Recl Trav Chim Pays-	HCAPLUS
van der Laan, A	1997	38	2249	Tetrahedron Lett	HCAPLUS
Will, D	1996		65	Innovation and Persp	HCAPLUS
Will, D	1995	51	12069	Tetrahedron	HCAPLUS
Woolf, T	1992	89	7305	Proc Natl Acad Sci	HCAPLUS

L50 ANSWER 7 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:310246 HCAPLUS
DN 131:88176
TI Synthesis of a monocharged **peptide nucleic acid** (**PNA**) analog and its recognition as substrate by DNA polymerases
AU Lutz, M. J.; **Will, D. W.**; **Breipohl, G.**; Benner, S. A.; **Uhlmann, E.**
CS Department of Chemistry, Swiss Federal Institute of Technology, Zurich, CH-8092, Switz.
SO Nucleosides & Nucleotides (1999), 18(3), 393-401
CODEN: NUNUD5; ISSN: 0732-8311
PB Marcel Dekker, Inc.
DT Journal
LA English
AB The prepn. of a novel phosphoramidite monomer based on thyminyl acetic acid coupled to the secondary nitrogen of 2-(2-amino-ethyl-amino)ethanol is described. This monomer can be used to attach a deoxy-nucleotide to the carboxy terminus of a **PNA** oligomer by solid-phase synthesis. The resulting **PNA** primer is recognized as a substrate by various DNA polymerases.
RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Breipohl, G				EP 0460446	HCAPLUS

Breipohl, G	1997	53	14671	Tetrahedron	
Egholm, M	1992	114	1895	J Am Chem Soc	HCAPLUS
Engels, J	1993	2	317	DNA Sythesis in Biot	
Hyrup, B	1996	4	5	Bioorg Med Chem	HCAPLUS
Lutz, M	1997	119	3177	J Am Chem Soc	HCAPLUS
Nielsen, P	1991	254	1497	Science	HCAPLUS
Uhlmann, E	1996	108	2793	Angew Chem Int Ed En	
Uhlmann, E	1998	37	2796	Angew Chem Int Ed En	HCAPLUS
Uhlmann, E	1990	90	543	Chem Rev	HCAPLUS
Uhlmann, E	1997	16	603	Nucleosides & Nucleo	HCAPLUS
Van der Laan, A	1998	8	663	Bioorg Med Chem Lett	HCAPLUS
Van der Laan, A	1997	38	2249	Tetrahedron Lett	HCAPLUS
Will, D	1995	51	12069	Tetrahedron	HCAPLUS

L50 ANSWER 8 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:91165 HCAPLUS
TI Minimal modification of antisense oligonucleotides
AU **Uhlmann, E.**
CS Chemical Research, Hoechst Marion Roussel, Frankfurt, 65926, Germany
SO Book of Abstracts, 217th ACS National Meeting, Anaheim, Calif., March 21-25 (1999), CARB-005 Publisher: American Chemical Society, Washington, D. C.
CODEN: 67GHA6
DT Conference; Meeting Abstract
LA English
AB Uniformly phosphorothioate (PS) modified oligodeoxynucleotides (ODN) are antisense agents of the first generation. Although a no. of PS-ODN are in advanced stages of clin. development and the first antisense drug (Vitravene; Isis Pharmaceuticals) has been approved by the FDA, certain limitations of PS-ODN have emerged. Our approach to overcome these limitations is to reduce the no. of PS linkages within the ODN to a min. which is necessary to stabilize against nucleotlytic degrdn. We have developed a novel protection strategy which is a combination of the end-capping technique and the PS protection of internal pyrimidine positions which are the major sites of endonuclease degrdn. This protection scheme has successfully been used for specific inhibition of expression of various genes. Advantageously, it can also be combined with secondary modifications at the carbohydrate moieties, such as 2'-O-alkyl-modifications, or with partial replacement of the sugar phosphate backbone by 2-aminoethylglycine-based **PNA** units (**peptide nucleic acid**) leading to DNA-**PNA** chimeras.

L50 ANSWER 9 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:745539 HCAPLUS
DN 130:66670
TI **PNA**: synthetic polyamide nucleic acids with unusual binding properties
AU **Uhlmann, Eugen**; Peyman, Anusch; **Breipohl, Gerhard**; **Will, David W.**
CS Hoechst Marion Rouseel Deutschland GmbH, Frankfurt am Main, D-65926, Germany
SO Angewandte Chemie, International Edition (1998), 37(20), 2796-2823
CODEN: ACIEF5; ISSN: 1433-7851
PB Wiley-VCH Verlag GmbH
DT Journal; General Review
LA English
AB A review with 160 refs. : since the investigation of oligonucleotides as potential therapeutics that target nucleic acids was initiated, the search for nucleic acid mimetics with improved properties, such as strengthened binding-affinity to complementary nucleic acids, increased biol. stability, and improved cellular uptake, has accelerated rapidly. In 1991 Nielsen et al. first described what is undoubtedly one of the most

interesting of the new derivs., the polyamide or **peptide nucleic acids** (**PNAs**), in which the entire sugar-phosphate backbone is replaced by an N-(2-aminoethyl)glycine polyamide structure. Since even minor structural changes in oligonucleotides, such as the replacement of an oxygen atom by sulfur (phosphorothioates), or by a neutral Me group (Me phosphonates), result in a decrease in binding affinity, it was even more astonishing to find that the drastic structural changes in **PNAs** result in nucleic acid mimetics with higher binding-affinity to complementary DNA and RNA than unmodified oligonucleotides. The remarkable binding properties of **PNAs** have spawned a rapidly expanding new field of research, where the targets are the synthesis of **PNAs** and **PNA** analogs, and their application as therapeutics, DNA diagnostics, and tools in biotechnol. In add., investigation of **PNAs** and **PNA** /DNA chimeras can be used to generate information on the structural and biol. properties of DNA and RNA themselves. Furthermore, they may trigger the generation of new ideas on models for alternative living systems and potential transitions between different genetic systems.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Akhtar, S	1997	18	12	Trends Pharm Sci	HCAPLUS
Albericio, F	1994	23	271	Pept Proc Eur Pept S	
Almarsson, O	1993	90	7518	Proc Natl Acad Sci U	HCAPLUS
Almarsson, O	1993	90	9542	Proc Natl Acad Sci U	HCAPLUS
Arlinghaus, H	1997	69	3747	Anal Chem	HCAPLUS
Bannwarth, W	1988	71	1517	Helv Chim Acta	HCAPLUS
Basu, S	1997	8	481	Bioconjugate Chem	HCAPLUS
Bergmann, F	1995	36	6823	Tetrahedron Lett	HCAPLUS
Betts, L	1995	270	1838	Science	HCAPLUS
Boffa, L	1996	271	13228	J Biol Chem	HCAPLUS
Boffa, L	1995	92	1901	Proc Natl Acad Sci U	HCAPLUS
Bohler, C	1995	376	578	Nature	HCAPLUS
Bonham, M	1995	23	1197	Nucleic Acids Res	HCAPLUS
Breipohl, G	1996	6	665	Bioorg Med Chem Lett	HCAPLUS
Breipohl, G	1996		S 61	Innovation and Persp	
Breipohl, G	1997	53	14671	Tetrahedron	
Brown, S	1994	265	777	Science	HCAPLUS
Buchardt, O	1993	11	384	Trends Biotechnol	HCAPLUS
Cantin, M	1997	38	4211	Tetrahedron Lett	HCAPLUS
Carlsson, C	1996	380	207	Nature	HCAPLUS
Castro, B	1990	11	900	Pept Chem Struct Bio	
Chen, S	1994	35	5105	Tetrahedron Lett	HCAPLUS
Cherny, D	1993	90	1667	Proc Natl Acad Sci U	HCAPLUS
Christensen, L	1995	1	175	J Pept Sci	MEDLINE
Christensen, L	1994	23	283	Pept Proc Eur Pept S	
Clivio, P	1997	119	5255	J Am Chem Soc	HCAPLUS
Cook, R	1994	35	6777	Tetrahedron Lett	HCAPLUS
Coste, J	1990	31	205	Tetrahedron Lett	HCAPLUS
Crooke, S	1996	36	107	Annu Rev Pharmacol T	HCAPLUS
de Mesmaeker, A	1995	5	343	Curr Opin Struct Bio	HCAPLUS
Demers, D	1995	23	3050	Nucleic Acids Res	HCAPLUS
Demidov, V	1994	48	1310	Biochem Pharmacol	HCAPLUS
Demidov, V	1993	21	2103	Nucleic Acids Res	HCAPLUS
Demidov, V	1994	22	5218	Nucleic Acids Res	HCAPLUS
Demidov, V	1995	92	2637	Proc Natl Acad Sci U	HCAPLUS
Diederichsen, U	1996	108	458	Angew Chem	
Diederichsen, U	1996	35	445	Angew Chem Int Ed En	HCAPLUS
Diederichsen, U	1996	37	475	Tetrahedron Lett	HCAPLUS
Dueholm, K	1994	4	1077	Bioorg Med Chem Lett	HCAPLUS
Dueholm, K	1994	59	5767	J Org Chem	HCAPLUS
Dueholm, K	1993	25	457	Org Prep Proced Int	HCAPLUS

Efimov, V	1996	61	S262	Collect Czech Chem C	HCAPLUS
Egholm, M	1992	114	1895	J Am Chem Soc	HCAPLUS
Egholm, M	1992	114	9677	J Am Chem Soc	HCAPLUS
Egholm, M	1993		800	J Chem Soc Chem Comm	HCAPLUS
Egholm, M	1993	365	566	Nature	HCAPLUS
Egholm, M	1995	23	217	Nucleic Acids Res	HCAPLUS
Englisch, U	1991	103	629	Angew Chem	HCAPLUS
Englisch, U	1991	30	613	Angew Chem Int Ed En	
Eriksson, M	1996	3	410	Nature Struct Biol	HCAPLUS
Famulok, M	1992	104	1001	Angew Chem	HCAPLUS
Famulok, M	1992	31	979	Angew Chem Int Ed En	
Finn, P	1996	24	3357	Nucleic Acids Res	HCAPLUS
Footer, M	1996	35	10673	Biochemistry	HCAPLUS
Gambacorti-Passerini, C	1996	88	1411	Blood	HCAPLUS
Gangamani, B	1996	52	15017	Tetrahedron	
Griffith, M	1995	117	831	J Am Chem Soc	HCAPLUS
Haaima, G	1996	108	2068	Angew Chem	
Haaima, G	1996	35	1939	Angew Chem Int Ed En	HCAPLUS
Hamilton, S	1997	36	11873	Biochemistry	HCAPLUS
Hansen, M	1997	203	199	J Immunol Methods	HCAPLUS
Hanvey, J	1992	258	1481	Science	HCAPLUS
Heimer, E	1984	23	203	Int J Pept Protein R	HCAPLUS
Helene, C	1993	4	29	Curr Opin Biotechnol	HCAPLUS
Hyrup, B	1996	4	5	Bioorg Med Chem	HCAPLUS
Hyrup, B	1996	6	1083	Bioorg Med Chem Lett	HCAPLUS
Hyrup, B	1994	116	7964	J Am Chem Soc	HCAPLUS
Hyrup, B	1993		518	J Chem Soc Chem Comm	HCAPLUS
Iyer, M	1995	270	14712	J Biol Chem	HCAPLUS
Jankowsky, E	1997	25	2690	Nucleic Acids Res	HCAPLUS
Jensen, K	1997	36	5072	Biochemistry	HCAPLUS
Jensen, K	1994	23	757	Pept Proc Eur Pept S	
Jordan, S	1997	7	681	Bioorg Med Chem Lett	HCAPLUS
Jordan, S	1997	7	687	Bioorg Med Chem Lett	HCAPLUS
Kastrup, J	1995	363	115	FEBS Lett	HCAPLUS
Kim, S	1993	115	6477	J Am Chem Soc	HCAPLUS
Knudsen, H	1996	24	494	Nucleic Acids Res	HCAPLUS
Koch, T	1997	49	80	J Pept Res	HCAPLUS
Koch, T	1995	36	6933	Tetrahedron Lett	HCAPLUS
Konig, W	1970	103	2034	Chem Ber	MEDLINE
Konig, W	1970	103	788	Chem Ber	MEDLINE
Konig, W	1991	21	143	Pept Proc Eur Pept S	
Koppelhus, U	1997	25	2167	Nucleic Acids Res	HCAPLUS
Kosynkina, L	1994	35	5173	Tetrahedron Lett	HCAPLUS
Krotz, A	1995	36	6937	Tetrahedron Lett	HCAPLUS
Lagriffoul, P	1994	4	1081	Bioorg Med Chem Lett	HCAPLUS
Lagriffoule, P	1997	3	912	Chem Eur J	HCAPLUS
Lansdorp, P	1996	5	685	Hum Mol Genet	HCAPLUS
Larsen, H	1996	24	458	Nucleic Acids Res	HCAPLUS
Le-Nguyen, D	1988		231	Pept Chem	
Leijon, M	1994	33	9820	Biochemistry	HCAPLUS
Lesnik, E	1997	25	568	Nucleic Acids Res	HCAPLUS
Lioy, E	1996		201	Liebigs Ann	HCAPLUS
Lowe, G	1997		539	J Chem Soc Perkin Tr	HCAPLUS
Lowe, G	1997		547	J Chem Soc Perkin Tr	HCAPLUS
Lutz, M	1997	119	3177	J Am Chem Soc	HCAPLUS
Mag, M	1989	17	5973	Nucleic Acids Res	HCAPLUS
Martinez, C	1997			Abstr Pap 213rd ACS	
Matteucci, M	1981	103	3185	J Am Chem Soc	HCAPLUS
Meier, C	1992	104	1039	Angew Chem	HCAPLUS
Meier, C	1992	31	1008	Angew Chem Int Ed En	
Mollegaard, N	1994	91	3892	Proc Natl Acad Sci U	HCAPLUS
Nielsen, P	1993	8	53	Anti-Cancer Drug Des	HCAPLUS
Nielsen, P	1994	149	139	Gene	HCAPLUS

Nielsen, P	1996	118	2287	J Am Chem Soc	HCAPLUS
Nielsen, P	1994	7	165	J Mol Recognit	HCAPLUS
Nielsen, P	1996	267	426	Methods Enzymol	HCAPLUS
Nielsen, P	1993	21	197	Nucleic Acids Res	HCAPLUS
Nielsen, P	1993	23	323	Origins Life Evol Bi	HCAPLUS
Nielsen, P	1991	254	1497	Science	HCAPLUS
Noble, S	1995	34	184	Drug Dev Res	HCAPLUS
Norton, J	1996	14	615	Nature Biotechnol	HCAPLUS
Oerum, H	1995	19	472	BioTechniques	HCAPLUS
Oerum, H	1993	21	5332	Nucleic Acids Res	HCAPLUS
Ono, A	1991	113	4032	J Am Chem Soc	HCAPLUS
Ono, A	1991	57	3225	J Org Chem	
Peffer, N	1993	90	10648	Proc Natl Acad Sci U	HCAPLUS
Perry-O'Keefe, H	1996	93	14670	Proc Natl Acad Sci U	HCAPLUS
Petersen, K	1995	5	1119	Bioorg Med Chem Lett	HCAPLUS
Petersen, K	1996	6	793	Bioorg Med Chem Lett	HCAPLUS
Peyman, A	1996	108	2797	Angew Chem	
Peyman, A	1997	109	2919	Angew Chem	
Peyman, A	1996	35	2636	Angew Chem Int Ed En	HCAPLUS
Peyman, A	1997	36	2809	Angew Chem Int Ed En	HCAPLUS
Peyman, A	1997	33	135	Antiviral Res	HCAPLUS
Peyman, A	1996	377	67	Biol Chem Hoppe-Seyl	HCAPLUS
Praseuth, D	1996	1309	226	Biochim Biophys Acta	HCAPLUS
Ramasamy, K	1996	6	1799	Bioorg Med Chem Lett	HCAPLUS
Rasmussen, H	1997	4	98	Nature Struct Biol	HCAPLUS
Reiter, M				unpublished results	
Richter, L	1995	5	1159	Bioorg Med Chem Lett	HCAPLUS
Rose, D	1993	65	3545	Anal Chem	HCAPLUS
Roush, W	1997	276	1192	Science	HCAPLUS
Schmidt, J	1996	235	239	Anal Biochem	HCAPLUS
Stetsenko, D	1996	37	3571	Tetrahedron Lett	HCAPLUS
Strobel, S	1991	350	172	Nature	HCAPLUS
Taylor, R	1997	15	212	Nature Genet	HCAPLUS
Thiede, C	1996	24	983	Nucleic Acids Res	HCAPLUS
Thisted, M	1996	3	358	Cell Vision	HCAPLUS
Thomson, S	1995	51	6179	Tetrahedron	HCAPLUS
Thuong, N	1993	105	697	Angew Chem	
Thuong, N	1993	32	666	Angew Chem Int Ed En	
Tomac, S	1996	118	5544	J Am Chem Soc	HCAPLUS
Uhlmann, E	1996	108	2793	Angew Chem	
Uhlmann, E	1996	35	2632	Angew Chem Int Ed En	
Uhlmann, E	1990	90	543	Chem Rev	HCAPLUS
Uhlmann, E	1997	1	64	Encyclopedia of Canc	
Uhlmann, E	1981	64	1688	Helv Chim Acta	HCAPLUS
Uhlmann, E	1997	16	603	Nucleosides Nucleoti	HCAPLUS
van der Laan, A	1995	114	295	Recl Trav Chim Pays-	HCAPLUS
van der Laan, A	1996	37	7857	Tetrahedron Lett	HCAPLUS
van der Laan, A	1997	38	2249	Tetrahedron Lett	HCAPLUS
Veselkov, A	1996	379	214	Nature	HCAPLUS
Veselkov, A	1996	24	2483	Nucleic Acids Res	HCAPLUS
Vickers, T	1995	23	3003	Nucleic Acids Res	HCAPLUS
Wang, J	1996	118	7667	J Am Chem Soc	HCAPLUS
Watkins, B	1982	104	5702	J Am Chem Soc	HCAPLUS
Weiler, J	1997	25	2792	Nucleic Acids Res	HCAPLUS
Wenninger, D	1997	16	761	Nucleosides Nucleoti	HCAPLUS
Wenninger, D	1997	16	977	Nucleosides Nucleoti	HCAPLUS
Will, D	1996		65	Innovation and Persp	HCAPLUS
Will, D	1995	51	12069	Tetrahedron	HCAPLUS
Wittung, P	1997	36	7973	Biochemistry	HCAPLUS
Wittung, P	1995	365	27	FEBS Lett	HCAPLUS
Wittung, P	1996	118	7049	J Am Chem Soc	HCAPLUS
Wittung, P	1997	119	3189	J Am Chem Soc	HCAPLUS
Wittung, P	1994	368	561	Nature	HCAPLUS

Wittung, P	1994	22	5371	Nucleic Acids Res	HCAPLUS
Xu, Y	1992	57	3839	J Org Chem	HCAPLUS
Zou, R	1987	65	1436	Can J Chem	HCAPLUS
Zuckermann, R	1992	114	10646	J Am Chem Soc	HCAPLUS

L50 ANSWER 10 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:667152 HCAPLUS
DN 130:66764
TI DNA-PHONA-**PNA** chimeric molecules: contributions to binding against complementary DNA
AU Peyman, A.; **Uhlmann, E.**; Wagner, K.; Augustin, S.; Weiser, C.; Hein, S.; Langner, D.; **Breipohl, G.**; **Will, D. W.**
CS Hoechst Marion Roussel Deutschland GmbH, Frankfurt, D-65926, Germany
SO Nucleosides & Nucleotides (1998), 17(9-11), 1997-2001
CODEN: NUNUD5; ISSN: 0732-8311
PB Marcel Dekker, Inc.
DT Journal
LA English
AB The synthesis of a DNA-phosphonate **peptide nucleic acid** analog (PHONA)-**peptide nucleic acid** (**PNA**) chimeric mol. using a monomethoxytrityl (Mmt) protection strategy is described. The chimeric oligomer shows duplex binding properties that are comparable to the corresponding **PNA**. Thus, PHONA building blocks can be incorporated into **PNAs** without distortion of the **PNA** structure.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
de Mesmaker, A	1995	28	366	Acc Chem Res	
Englisch, U	1991	30	613	Angew Chem Int Ed En	
Hyrup, B	1996	4	5	Bioorganic & Medicin	HCAPLUS
Peyman, A	1996	35	2636	Angew Chem Int Ed En	HCAPLUS
Peyman, A				Angew Chem in the pr	
Uhlmann, E	1996	35	2632	Angew Chem Int Ed En	
Uhlmann, E				Angew Chem submitted	
Uhlmann, E	1990	90	543	Chem Rev	HCAPLUS
Uhlmann, E	1997		64	Enzyclopedia of Canc	
Will, D	1995	51	12069	Tetrahedron	HCAPLUS

L50 ANSWER 11 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:618936 HCAPLUS
DN 129:227036
TI **Peptide nucleic acids** (**PNA**) and **PNA**-DNA chimeras. From high binding affinity towards biological function
AU **Uhlmann, Eugen**
CS Hoechst Marion Roussel Deutschland G.m.b.H., Frankfurt/Main, D-65926, Germany
SO Biological Chemistry (1998), 379(8/9), 1045-1052
CODEN: BICHF3; ISSN: 1431-6730
PB Walter de Gruyter & Co.
DT Journal; General Review
LA English
AB A review is given with 45 refs. Oligonucleotide analogs are of major interest as tools in mol. biol., as diagnostics, and as potential pharmaceuticals which bind in a predictable way to certain nucleic acid target sequences, aiming at the inhibition of expression of disease-causing genes. One of the most promising **nucleic acid** mimetics are the **peptide**- or polyamide-**nucleic acids** (**PNA**) which bind with higher affinity to DNA and RNA than natural **oligonucleotides**. In these non-ionic **PNAs**, the entire sugar-phosphate backbone is replaced

by an N-amino-ethylglycine-based polyamide structure. A unique property of **PNA** is its ability to displace one strand of a DNA double-helix. This strand displacement process, which is inefficient with DNA, is supported by the formation of an unusually stable internal (**PNA**), DNA triple helix. The combination of **PNA** and DNA in 1 mol. results in **PNA**/DNA chimeras with new properties. They show improved aq. soly. compared to pure **PNAs** due to their partially neg. charged structure. The cellular uptake of the chimeras is better than of pure **PNAs**. In contrast to **PNA**, the chimeras bind exclusively in the antiparallel orientation under physiol. conditions. The binding affinity is generally stronger when the **PNA**/DNA chimeras are hybridized to RNA than to DNA, whereby the strength of binding strongly depends on the **PNA**: DNA ratio. **PNA**/DNA chimeras are recognized as substrates by various nucleic acid processing enzymes, and consequently can also assume biol. functions, such as a primer function for DNA polymerases. Pure **PNA** cannot induce RNase H cleavage of target RNA, which is believed to support the biol. efficacy of antisense agents. DNA-**PNA** chimeras are able to stimulate cleavage of the target RNA by RNase H upon formation of an RNA chimera duplex.

L50 ANSWER 12 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:220217 HCAPLUS
DN 128:321903
TI Optimization of the binding properties of **PNA**-(5')-DNA chimerae
AU van der Laan, A. C.; Havenaar, P.; Oosting, R. S.; Kuyl-Yeheskiely, E.; **Uhlmann, E.**; van Boom, J. H.
CS Gorlaeus Lab., Leiden Inst. of Chemistry, Leiden, 2300 RA, Neth.
SO Bioorganic & Medicinal Chemistry Letters (1998), 8(6), 663-668
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
GI



AB The synthesis and evaluation of **PNA**-(5')-DNA chimera contg. either a 5'-amide (i.e. I; T = thymin-1-yl), a 5'-phosphodiester (i.e. II)

or 5'-phosphonate linkages (i.e. III; R = H, thymin-1-ylacetyl) at the junction site are described. The 5'-linkages were installed using protected phosphoramidite and phosphonate building blocks. It is shown that **PNA**-(5')-DNA of types I, II, and III (R = thymin-1-ylacetyl) have a higher binding affinity with complementary RNA than native DNA, and that the antisense activity is mainly due to RNase H.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bergmann, F	1995	36	6823	Tetrahedron Lett	HCAPLUS
Cazenave, C	1993	75	113	Biochimie	HCAPLUS
Dangles, O	1987	52	4984	J Org Chem	HCAPLUS
Egholm, M	1992	114	1895	J Am Chem Soc	HCAPLUS
Eriksson, M	1996	3	410	Nature Struct Biolog	HCAPLUS
Eriksson, M	1997	16	617	Nucleosides and Nucl	HCAPLUS
Knudsen, H	1996	24	494	Nucl Acids Res	HCAPLUS
Nielsen, P	1993	8	53	Anti Cancer Drug Des	HCAPLUS
Nielsen, P	1991	241	1497	Science	
Orum, H	1995	19	472	BioTechniques	MEDLINE
Smith, L	1987	155	260	Methods in Enzymolog	HCAPLUS
Uhlmann, E	1996	35	2632	Angew Chem Int Ed En	
van der Laan, A	1996	37	7857	Tetrahedron Lett	HCAPLUS
van der Laan, A	1997	38	2249	Tetrahedron Lett	HCAPLUS
Will, D	1995	51	12069	Tetrahedron	HCAPLUS

L50 ANSWER 13 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:186571 HCAPLUS
DN 128:240314
TI A **nucleic acid** amplification method using **peptide nucleic acids** as primers for thermostable DNA polymerases
IN **Uhlmann, Eugen**; **Breipohl, Gerhard**; Benner, Steven; Lutz, Michael
PA Hoechst A.-G., Germany
SO Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 829542	A1	19980318	EP 1997-115521	19970908
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
DE 19637339	A1	19980319	DE 1996-19637339	19960913
US 6063571	A	20000516	US 1997-927274	19970911
CA 2215489	AA	19980313	CA 1997-2215489	19970912
JP 10099088	A2	19980421	JP 1997-250443	19970916
PRAI DE 1996-19637339		19960913		

AB A method of using **peptide nucleic acids** (**PNAs**) as primers for DNA amplification with thermostable DNA polymerases, i.e. in PCR, is described. The only modification to the **PNAs** that is essential is the introduction of 1-3 3'-terminal deoxynucleotides with a free 3'-hydroxyl group. Methods for the synthesis of deoxynucleotide-terminated primers are also given.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Amersham Int Plc				WO 9508556 A	HCAPLUS
Boehringer Mannheim Gmb				EP 0736608 A	HCAPLUS
Hoechst Ag				EP 0672677 A	HCAPLUS

Stratagene Inc | | | |WO 9516028 A |HCAPLUS

L50 ANSWER 14 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:70167 HCAPLUS
DN 128:167687
TI PHONA - **PNA** co-oligomers: nucleic acid mimetics with interesting properties
AU Peyman, Anusch; **Uhlmann, Eugen**; Wagner, Konrad; Augustin, Sascha; Weiser, Caroline; **Will, David W.**; **Breipohl, Gerhard**
CS Hoechst Marion Roussel Deutschland GmbH, Frankfurt, D-65926, Germany
SO Angewandte Chemie, International Edition in English (1998), Volume Date 1997, 36(24), 2809-2812
CODEN: ACIEAY; ISSN: 0570-0833
PB Wiley-VCH Verlag GmbH
DT Journal
LA English
GI



AB Alternating title co-oligomer I contg. **peptide nucleic acid** (**PNA**) and (aminomethyl)phosphonic acid backbones was prepd. and melting temps. (Tm) of complexes with completely or partially complementary DNA measured. The binding properties of I with complementary DNA are very similar to those of **PNAs**, but the co-oligomer I has a much better water soly.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Agrawal, S	1996			Methods in Molecular	
Bergmann, F	1995	36	6823	Tetrahedron Lett	HCAPLUS
Carpino, L	1993	115	4397	J Am Chem Soc	HCAPLUS
de Mesmaker, A	1995	28	366	Acc Chem Res	
Egholm, M	1992	114	9677	J Am Chem Soc	HCAPLUS
Englisch, U	1991	103	629	Angew Chem	HCAPLUS
Englisch, U	1991	30	613	Angew Chem Int Ed En	
Eriksson, M	1996	3	410	Nature Structural Bi	HCAPLUS
Finn, P	1996	24	3357	Nucl Acids Res	HCAPLUS
Griffith, M	1995	117	831	J Am Chem Soc	HCAPLUS
Hanvey, J	1992	258	1481	Science	HCAPLUS
Hayakawa, Y	1993	58	5551	J Org Chem	HCAPLUS
Hyrup, B	1996	4	5	Bioorg Med Chem	HCAPLUS
Job, P	1928	9	113	Ann Chim (Paris)	HCAPLUS
Kunz, H	1984	96	426	Angew Chem	HCAPLUS
Kunz, H	1984	23	436	Angew Chem Int Ed En	

Nielsen, P	1995	24	167	Annu Rev Biophys Bio	HCAPLUS
Petersen, K	1995	5	1119	Bioorg Med Chem Lett	HCAPLUS
Peyman, A	1996			EP 0739898 A2	HCAPLUS
Peyman, A	1996	108	2797	Angew Chem	
Peyman, A	1996	35	2636	Angew Chem Int Ed En	HCAPLUS
Reese, C	1978	34	3143	Tetrahedron	HCAPLUS
Shikata, H	1995	125	421	J Lab Clin Med	HCAPLUS
Trapane, T	1996	35	5495	Biochemistry	HCAPLUS
Uhlmann, E	1996	108	2793	Angew Chem	
Uhlmann, E	1996	35	2632	Angew Chem Int Ed En	
Uhlmann, E	1990	90	543	Chem Rev	HCAPLUS
Uhlmann, E	1997		64	Encyclopedia of Canc	
Uhlmann, E	1981	64	1688	Helv Chim Acta	HCAPLUS
Uhlmann, E	1993		355	Methods in Molecular	HCAPLUS
van der Laan, A	1995	114	295	Recl Trav Chim Pays-	HCAPLUS
van der Laan, A	1996	37	7857	Tetrahedron Lett	HCAPLUS
Will, D	1995	51	12069	Tetrahedron	HCAPLUS

L50 ANSWER 15 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:758327 HCAPLUS
Correction of: 1997:714702
DN 127:346655
Correction of: 127:319261
TI Novel synthetic routes to **PNA** monomers and **PNA**-DNA linker molecules
AU **Breipohl, Gerhard; Will, David W.**; Peyman, Anusch; **Uhlmann, Eugen**
CS Hoechst Marion Roussel Deutschland GmbH, Frankfurt am Main, D-65926, Germany
SO Tetrahedron (1997), 53(43), 14671-14686
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier
DT Journal
LA English
GI



AB Novel methods for the prepn. of monomethoxytrityl (Mmt)-protected aminoethylglycine building blocks [I; B = 1-thyminyl, N4-(4-methoxybenzoyl)-1-cytosinyl, N6-(4-methoxybenzoyl)-9-adeninyl, N2-acetyl-O6-diphenylcarbamoyl-9-guaninyl, N2-isobutyryl-9-guaninyl] and dimethoxytrityl (Dmt)-protected hydroxyethylglycine derivs. II, useful for the synthesis of polyamide nucleic acids (**PNAs**) and **PNA** /DNA chimeras, are described. The protecting group strategy employed for **PNA** monomer synthesis produces intermediates that are easily isolated, minimizes chromatog. purifn., and is suitable for large-scale monomer synthesis.

L50 ANSWER 16 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:714702 HCAPLUS
DN 127:319261
TI Novel synthetic routes to **PNA** monomers and **PNA**-DNA linker molecules

AU **Breipohl, Gerhard; Will, David W.**; Peyman, Anusch; Uhimann, Eugen
CS Hoechst Marion Roussel Deutschland GmbH, Frankfurt am Main, D-65926, Germany
SO Tetrahedron (1997), 53(43), 14671-14686
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier
DT Journal
LA English
GI



AB Novel methods for the prepn. of monomethoxytrityl (Mmt)-protected aminoethylglycine building blocks I [B = 1-thyminyl, N4-(4-methoxybenzoyl)-1-cytosinyl, N6-(4-methoxybenzoyl)-9-adeninyl, N2-acetyl-O6-diphenylcarbamoyl-9-guaninyl, N2-isobutyryl-9-guaninyl] and dimethoxytrityl (Dmt)-protected hydroxyethylglycine derivs. II, useful for the synthesis of polyamide nucleic acids (**PNAs**) and **PNA** /DNA chimeras are described. The protecting group strategy employed for **PNA** monomer synthesis produces easily isolable intermediates, minimizes chromatog. purifn., and is suitable for large-scale monomer synthesis.

L50 ANSWER 17 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:591221 HCAPLUS
DN 127:262910
TI Synthesis of polyamide nucleic acids (**PNAs**), **PNA** /DNA-chimeras and phosphonic ester nucleic acids (PHONAs)
AU **Uhlmann, E.; Will, D. W.; Breipohl, G.**; Peyman, A.; Langner, D.; Knolle, J.; O'Malley, G.
CS Central Pharma Res., Hoechst AG, Frankfurt, D-65926, Germany
SO Nucleosides & Nucleotides (1997), 16(5 & 6), 603-608
CODEN: NUNUD5; ISSN: 0732-8311
PB Dekker
DT Journal; General Review
LA English
AB A review with 18 refs. on methods for the prepn. of polyamide nucleic acids (**PNAs**) and derivs. thereof by different synthetic routes is described. The first strategy makes use of 9-Fluorenylmethoxycarbonyl (Fmoc)/monomethoxytrityl (Mmt) protected building blocks, whereas the second approach involves the use of Mmt/acyl protected monomers, which allows the prepn. of **PNA**/DNA chimera. Addnl., a block coupling strategy is presented for the synthesis of novel phosphonic ester nucleic acids (PHONAs).

L50 ANSWER 18 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:412349 HCAPLUS
DN 127:66087
TI Solid-phase synthesis of **PNA**-DNA chimeric oligomers
AU **Will, D.W.; Breipohl, G.**; Langner, D.; **Uhlmann, E.**
CS Hoechst AG, Allgemeine Pharma Forschung G838, Frankfurt am Main, D-65926, Germany

SO Innovation and Perspectives in Solid Phase Synthesis & Combinatorial Libraries: Peptides, Proteins and Nucleic Acids--Small Molecule Organic Chemical Diversity, Collected Papers, International Symposium, 4th, Edinburgh, Sept. 12-16, 1995 (1996), Meeting Date 1995, 65-68. Editor(s): Epton, Roger. Publisher: Mayflower Scientific, Birmingham, UK. CODEN: 64ONA9
DT Conference
LA English
AB A symposium on **PNA**-DNA chimeric oligomers have been prepd. using automated solid-phase prepn. A novel Mmt protecting-group strategy for the **PNA** part of the mol. was employed which allowed the use of std. DNA synthesis and deprotection chem.

L50 ANSWER 19 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:412348 HCAPLUS
DN 127:66086
TI Synthesis of polyamide nucleic acids using a new protection scheme which is fully compatible with oligonucleotide synthesis
AU **Breipohl, G.**; **Will, D.W.**; Langner, D.; Knolle, J.; **Uhlmann, E.**
CS Hoechst AG, Allgemeine Pharma Forschung G838, Frankfurt am Main, D-65926, Germany
SO Innovation and Perspectives in Solid Phase Synthesis & Combinatorial Libraries: Peptides, Proteins and Nucleic Acids--Small Molecule Organic Chemical Diversity, Collected Papers, International Symposium, 4th, Edinburgh, Sept. 12-16, 1995 (1996), Meeting Date 1995, 61-64. Editor(s): Epton, Roger. Publisher: Mayflower Scientific, Birmingham, UK. CODEN: 64ONA9
DT Conference
LA English
AB A symposium on the prepn. of novel monomethoxytrityl (Mmt) protected monomers for the prepn. of polyamide nucleic acids (**PNAs**) is described. Use of the acid-labile Mmt group as temporary protection for the primary amino function of aminoethylglycine in combination with base-labile acyl-type protecting groups for the nucleobases allow a synthetic strategy similar to std. oligo-nucleotide synthesis conditions. **PNAs** of mixed base sequence have been synthesized with this method.

L50 ANSWER 20 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:380031 HCAPLUS
Correction of: 1996:755988
DN 127:2136
Correction of: 126:141081
TI Synthesis and properties of **PNA**/DNA chimeras
AU **Uhlmann, Eugen**; **Will, David W.**; **Breipohl, Gerhard**; Langner, Dietrich; Ryte, Antonina
CS Hoechst AG, Frankfurt/Main, D-65926, Germany
SO Angewandte Chemie, International Edition in English (1996), 35(22), 2632-2635
CODEN: ACIEAY; ISSN: 0570-0833
PB VCH
DT Journal
LA English
AB We have developed a generally applicable method for the automated synthesis of DNA/**PNA** chimeras. This method is fully compatible with std. DNA synthesis methods and requires no addnl. deprotection steps at the end of oligomer synthesis. The binding affinity of DNA-**PNA** chimeras is higher than that of the comparable DNA-phosphorothioate chimeras or natural oligonucleotides. Unlike pure **PNAs**, the DNA-**PNA** chimeras investigated bind only in the antiparallel orientation to their complementary nucleic acids under physiol conditions.

L50 ANSWER 21 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:283607 HCAPLUS
DN 126:264359
TI Preparation of ethylglycine derivatives
IN **Breipohl, Gerhard; Uhlmann, Eugen; Will, David William**
PA Hoechst A.-G., Germany
SO Ger. Offen., 14 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19532553	A1	19970306	DE 1995-19532553	19950904
	EP 761681	A2	19970312	EP 1996-113530	19960822
	EP 761681	A3	19970709		
	EP 761681	B1	20020313		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AT 214398	E	20020315	AT 1996-113530	19960822
	ES 2173230	T3	20021016	ES 1996-113530	19960822
	AU 9664408	A1	19970306	AU 1996-64408	19960902
	AU 708034	B2	19990729		
	CA 2184681	AA	19970305	CA 1996-2184681	19960903
	NO 9603677	A	19970305	NO 1996-3677	19960903
	JP 09124572	A2	19970513	JP 1996-232692	19960903
	US 5817811	A	19981006	US 1996-707149	19960903
PRAI	DE 1995-19532553	A	19950904		

OS MARPAT 126:264359
AB N-ethylglycine derivs. PG-X-CH2CH2N(COCH2B1)CH2CO2H (PG is a urethane- or trityl-type amino protecting group which is cleavable by weak acid; X = NH or O; B1 = nucleotide base in which exocyclic amino or hydroxy groups are protected), useful in **PNA** or **PNA**/DNA hybrid prepn., were prepd. Thus, 2-aminoethanol was condensed with bromoacetic acid t-Bu ester, then with thyminylacetic acid, the product deesterified, and the acid treated with DMT-Cl to give a protected **PNA** monomer.

L50 ANSWER 22 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:224058 HCAPLUS
DN 126:274010
TI Recognition of Uncharged Polyamide-Linked Nucleic Acid Analogs by DNA Polymerases and Reverse Transcriptases
AU Lutz, Michael J.; Benner, Steven A.; Hein, Silvia; **Breipohl, Gerhard; Uhlmann, Eugen**
CS Department of Chemistry, Swiss Federal Institute of Technology, Zurich, CH-8092, Switz.
SO Journal of the American Chemical Society (1997), 119(13), 3177-3178
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
AB Polyamide-linked nucleic acid (**PNAs**) are DNA mimics in which the deoxyribose phosphate backbone is replaced by uncharged N-(2-aminoethyl)glycine units. Here, the authors report that several DNA polymerases and reverse transcriptases are able to elongate a **PNA** primer with a nucleophilic 3'-hydroxyl group, despite the fact that no phosphate residues are present in the **PNA** primer to interact with the polymerase. Enzymic synthesis of **PNA**-DNA chimeras might have implications for the use of modified **PNAs** in advanced diagnostic systems, allowing facilitated screening for genetic mutations, and as tools for studying structure-function relationships in enzymes that process nucleic acids. These results are also interesting in the light of models for the origin of life that propose an evolutionary linkage between

a **PNA**-like and a DNA-protein world.

L50 ANSWER 23 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1996:755988 HCAPLUS
DN 126:141081
TI Synthesis and properties of **PNA**/DNA chimeras
AU **Uhlmann, Eugen; Will, David W.; Breiphohl, Gerhard**; Langner, Dietrich; Ryte, Antonina
CS Hoechst AG, Frankfurt/Main, D-65926, Germany
SO Angewandte Chemie, International Edition in English (1996), 35(22), 2632-2635
CODEN: ACIEAY; ISSN: 0570-0833
PB VCH
DT Journal
LA English
AB We have developed a generally applicable method for the automated synthesis of DNA/**PNA** chimeras. This method is fully compatible with std. DNA synthesis methods and requires no addnl. deprotection steps at the end of oligomer synthesis. The binding affinity of DNA-**PNA** chimeras is higher than that of the comparable DNA-phosphorothioate chimeras or natural oligonucleotides. Unlike pure **PNAs**, the DNA-**PNA** chimeras investigated bind only in the antiparallel orientation to their complementary nucleic acids under physiol. conditions.

L50 ANSWER 24 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1996:508642 HCAPLUS
Correction of: 1996:190218
DN 125:168639
Correction of: 124:344062
TI Synthesis of polyamide nucleic acids (**PNAs**) using a novel Fmoc/Mmt protecting-group combination
AU **Breipohl, G.**; Knolle, J.; Langner, D.; O'Malley, G.; **Uhlmann, E.**
CS Central Pharma Res., Hoechst AG, Frankfurt, 65926, Germany
SO Bioorganic & Medicinal Chemistry Letters (1996), 6(6), 665-670
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier
DT Journal
LA English
AB The prepn. of 9-fluorenylmethoxycarbonyl (Fmoc) protected building blocks for the synthesis of polyamide nucleic acids (**PNAs**) is described. Use of 4-methoxyphenyldiphenylmethyl (Mmt)-protecting groups for the exocyclic amino function of the nucleobases enhances the soly. of the monomers and allows final deprotection by mild acid treatment. The novel synthetic route is exemplified by the synthesis of heptameric and octameric **PNAs**.

L50 ANSWER 25 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1996:190218 HCAPLUS
DN 124:344062
TI Synthesis of polyamide nucleic acids (**PNAs**) using a novel Fmoc/Mmt protecting-group combination
AU Breipohol, G.; Knolle, J.; Langner, D.; O, Malley, G.; **Uhlmann, E.**
CS Central Pharma Research, Hoechst AG, Frankfurt, 65926, Germany
SO Bioorganic & Medicinal Chemistry Letters (1996), 6(6), 665-70
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier
DT Journal
LA English
AB The prepn. of 9-fluorenylmethoxycarbonyl (Fmoc) protected building blocks for the synthesis of polyamide nucleic acids (**PNAs**) is described. Use of 4-methoxyphenyldiphenylmethyl (Mmt)-protecting groups

for the exocyclic amino function of the nucleobases enhances the soly. of the monomers and allows final deprotection by mild acid treatment. The novel synthetic route is exemplified by the synthesis of heptameric and octameric **PNAs**.

L50 ANSWER 26 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1996:47656 HCAPLUS
DN 124:199545
TI Activation of c-Fos contributes to amyloid .beta.-peptide-induced neurotoxicity
AU Gillardon, F.; Skutella, T.; **Uhlmann, E.**; Holsboer, F.; Zimmermann, M.; Behl, C.
CS II. Physiologisches Institut der Universitaet Heidelberg, INF 326, Heidelberg, 69120, Germany
SO Brain Research (1996), 706(1), 169-72
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier
DT Journal
LA English
AB Amyloid .beta. peptide, a major component of Alzheimer's disease plaques, is directly toxic to various neuronal cell lines and primary neurons in culture. The mechanism underlying A.beta. neurotoxicity may include an increase in intracellular calcium and reactive oxygen species. In the present study, exposure of a mouse hippocampal cell line (HT-22) to the 25-35 peptide fragment of A.beta. (10 .mu.M) caused a rapid and sustained increase in nuclear c-Fos immunoreactivity. Inhibition of A.beta.-mediated c-Fos activation by c-fos antisense oligodeoxynucleotides (5 .mu.M) significantly protected against A.beta. toxicity as assessed by MTT assay. The signal transduction pathway for c-fos induction remains speculative, however, there seems to be a causal relationship between c-Fos transcription factor and A.beta. toxicity.

L50 ANSWER 27 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1995:994444 HCAPLUS
DN 124:202955
TI Preparation of polyamide-oligonucleotide derivatives as drugs, gene probes, and primers.
IN **Uhlmann, Eugen; Breipohl, Gerhard**
PA Hoechst A.-G., Germany
SO Eur. Pat. Appl., 51 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 672677	A2	19950920	EP 1995-103332	19950308
	EP 672677	A3	19960117		
	EP 672677	B1	20020703		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	DE 4408528	A1	19950928	DE 1994-4408528	19940314
	EP 1113021	A2	20010704	EP 2001-104012	19950308
	EP 1113021	A3	20010711		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	AT 220070	E	20020715	AT 1995-103332	19950308
	ES 2179080	T3	20030116	ES 1995-103332	19950308
	FI 9501132	A	19950915	FI 1995-1132	19950310
	AU 9514798	A1	19950921	AU 1995-14798	19950310
	AU 698210	B2	19981029		
	CA 2144475	AA	19950915	CA 1995-2144475	19950313
	NO 9500955	A	19950915	NO 1995-955	19950313
	CN 1112126	A	19951122	CN 1995-102946	19950313
	JP 07278179	A2	19951024	JP 1995-54644	19950314

PRAI DE 1994-4408528 A 19940314
EP 1995-103332 A3 19950308
AB F[(QB)q(Q1B)r(Q2B)s(Q3B)t]xF1 [q, r, s, t = 0, 1; X = 1-20; Q, Q2 = nucleic acid (deriv.); Q1, Q3 = polyamide residue contg. .gtoreq.1 nucleic acid base except thymine; B = covalent bond, org. residue contg. .gtoreq.1 of C, N, O, S; F, F1 = end groups which may be bound to each other], were prepd. Title compds. show increased cellular uptake, improved nuclease stability, and are not cytotoxic; they are claimed for use as drugs and gene probes.

L50 ANSWER 28 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1995:994428 HCAPLUS
DN 124:87805
TI **Peptide nucleic acid** synthesis using an amino protecting group which is labile to weak acids.
IN **Breipohl, Gerhard Dr; Uhlmann, Eugen Dr**
PA Hoechst A.-G., Germany
SO Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 672700	A1	19950920	EP 1995-103318	19950308
EP 672700	B1	19990602		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4408531	A1	19950928	DE 1994-4408531	19940314
AT 180805	E	19990615	AT 1995-103318	19950308
ES 2132450	T3	19990816	ES 1995-103318	19950308
FI 9501130	A	19950915	FI 1995-1130	19950310
AU 9514801	A1	19950921	AU 1995-14801	19950310
AU 695931	B2	19980827		
CA 2144477	AA	19950915	CA 1995-2144477	19950313
NO 9500957	A	19950915	NO 1995-957	19950313
JP 07285989	A2	19951031	JP 1995-54642	19950314
US 6046306	A	20000404	US 1997-927178	19970911
PRAI DE 1994-4408531		19940314		
US 1995-402385		19950313		

AB RAk(XB1)nQ1Q1 [XB = NH(CH2)fCH2N(COCH2B)(CH2)fO, NHCH[(CH2)fB]CONHCH2CO, NHCH[(CH2)fB](CH2)3CO, etc.; f = 1-4; k, l = 0-10; A, Q = amino acid residue; B = (un)natural nucleic acid base or prodrug or replacement forms thereof; Q1 = OH, amino], were prepd. by solid phase synthesis. Thus, H-[Aeg(T)]3hex [Aeg(T) = N-(2-aminoethyl)-N-[(1-thyminyl)acetyl]glycyl, hex = HN(CH2)6OH] was prepd. on hex-succ-tentagel (succ = succinoyl) (prepn. given) on a DNA synthesizer.

L50 ANSWER 29 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1995:994427 HCAPLUS
DN 124:87804
TI **Peptide nucleic acid** synthesis using a base labile amino protecting group.
IN **Breipohl, Gerhard Dr; Uhlmann, Eugen Dr**; Knolle, Jochen Dr
PA Hoechst A.-G., Germany
SO Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 672701	A1	19950920	EP 1995-103319	19950308

	EP 672701	B1	19990728		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	DE 4408533	A1	19950928	DE 1994-4408533	19940314
	AT 182602	E	19990815	AT 1995-103319	19950308
	ES 2136755	T3	19991201	ES 1995-103319	19950308
	FI 9501129	A	19950915	FI 1995-1129	19950310
	AU 9514800	A1	19950921	AU 1995-14800	19950310
	AU 683714	B2	19971120		
	CA 2144473	AA	19950915	CA 1995-2144473	19950313
	NO 9500958	A	19950915	NO 1995-958	19950313
	JP 07291909	A2	19951107	JP 1995-54641	19950314
	US 6121418	A	20000919	US 1997-967197	19971029
	US 6316595	B1	20011113	US 2000-495457	20000201
PRAI	DE 1994-4408533	A	19940314		
	US 1995-402844	B1	19950313		
	US 1997-967197	A3	19971029		

AB RAk[NHCH2CH2N(COCH2B)CH2CO]nQlQ1 (R = H, alkanoyl, alkoxycarbonyl, cycloalkanoyl, aroyl, heteroaroyl, group which promotes intracellular uptake or interacts with target nucleic acids; A, Q = amino acid residue; Q1 = OH, amino; B = nucleobase or prodrug form thereof; l = 0-20; n = 1-50), were prepd. by solid phase synthesis. Thus, H-[Aeg(T)]8-Lys-NH2 [Aeg(T) = N-(2-aminoethyl)-N-[(1-thyminyl)acetyl]glycyl] was prepd. by coupling of FMOC-Lys(BOC)-OH and FMOC-Aeg(T)-OH (prepn. given) on 5-(FMOC-amino-4-methoxybenzyl)-2,4-dimethoxyphenylpropionic acid-derivatized aminomethylpolystyrene resin using an activator soln. of PyBOP (PyBOP = benzotriazolyl-1-oxytripyrrolidiniophosphonium hexafluorophosphate) in DMF, NEM (N-ethylmorpholine) in DMF as base for activation, and 20% piperidine in DMF for deprotection.

L50 ANSWER 30 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1995:994426 HCAPLUS
DN 124:87803
TI Preparation of substituted N-ethylglycine derivatives for the preparation of **peptide nucleic acids** and **peptide nucleic acid/deoxyribonucleic** acid hybrids.
IN **Breipohl, Gerhard; Uhlmann, Eugen**; Knolle, Jochen
PA Hoechst A.-G., Germany
SO Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 672661	A1	19950920	EP 1995-103333	19950308
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	DE 4408534	A1	19950928	DE 1994-4408534	19940314
	FI 9501128	A	19950915	FI 1995-1128	19950310
	AU 9514799	A1	19950921	AU 1995-14799	19950310
	AU 686729	B2	19980212		
	CA 2144474	AA	19950915	CA 1995-2144474	19950313
	NO 9500959	A	19950915	NO 1995-959	19950313
	US 6075143	A	20000613	US 1995-402840	19950313
	JP 07258222	A2	19951009	JP 1995-54643	19950314
	US 6465650	B1	20021015	US 2000-506901	20000218
PRAI	DE 1994-4408534	A	19940314		
	US 1995-402840	A3	19950313		

OS MARPAT 124:87803
AB PGXCH2CH2N(COYB)CH2CO2H [PG = urethane- or trityl-type protecting group labile to weak acid; X = NH, O, S; Y = CH2, NH, O; B = (protected) nucleoside (replacement) base], were prepd. Thus, N-[(4-methoxyphenyl)diphenylmethyl]aminoethylglycine Me ester (prepn. given) in DMF was treated sequentially with 3,4-dihydro-4-oxo-1,2,3-benzotriazine,

4-ethylmorpholine, N4-benzoyl-N1-carboxymethylcytosine in DMF, and with DCC; the mixt. was stirred 20 h at room temp. to give the coupling product, which was sapond. with aq. NaOH/dioxane to give N-[(4-methoxyphenyl)diphenylmethyl]aminoethyl-N-[[1-(N4-benzoyl)cytosyl]acetyl]glycine.

L50 ANSWER 31 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1995:908968 HCAPLUS
DN 124:117857
TI The synthesis of polyamide nucleic acids using a novel monomethoxytrityl protecting-group strategy
AU **Will, David W.**; **Breipohl, Gerhard**; Langner, Dietrich; Knolle, Jochen; **Uhlmann, Eugen**
CS Hoechst AG, Allgemeine Pharma Forschung G838, Frankfurt am Main, D-65926, Germany
SO Tetrahedron (1995), 51(44), 12069-82
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier
DT Journal
LA English
OS CASREACT 124:117857
AB The prepn. of 4-MeOC6H4CPh2NHCH2CH2N(COCH2R)CH2CO2Me (R = thymine, N4-tert-butylbenzoylcytosine, N6-anisoyladenine, N2-isobutanoylguanine) for the synthesis of polyamide nucleic acids (**PNAs**) is described. The use of base-labile acyl-type nucleobase protecting groups, including monomethyltrityl N-protection of H2NCH2CH2NhCH2CO2Me, and of a succinyl-linked solid-support offers a synthetic strategy similar to std. oligonucleotide synthesis conditions. This strategy has been successfully applied for the synthesis of **PNAs** of mixed base sequence.

L50 ANSWER 32 OF 34 HCAPLUS COPYRIGHT 2003 ACS
AN 1991:443507 HCAPLUS
DN 115:43507
TI Fusion proteins, their preparation and use
IN Stengelin, Siegfried; Ulmer, Wolfgang; Habermann, Paul; **Uhlmann, Eugen**; Seed, Brian
PA Hoechst A.-G., Germany; General Hospital Corp.
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9103550	A1	19910321	WO 1990-US4840	19900828
	W: AU, CA, FI, HU, JP, KR, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	IL 95495	A1	19961016	IL 1990-95495	19900827
	CA 2065146	AA	19910301	CA 1990-2065146	19900828
	AU 9062872	A1	19910408	AU 1990-62872	19900828
	AU 638277	B2	19930624		
	EP 489780	A1	19920617	EP 1990-912715	19900828
	EP 489780	B1	19981104		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	HU 60327	A2	19920828	HU 1992-674	19900828
	JP 05501799	T2	19930408	JP 1990-512297	19900828
	JP 3043803	B2	20000522		
	AT 173018	E	19981115	AT 1990-912715	19900828
	ES 2124216	T3	19990201	ES 1990-912715	19900828
	HU 216069	B	19990428	HU 1974-92006	19900828
	ZA 9006839	A	19910626	ZA 1990-6839	19900928
	NO 9200774	A	19920428	NO 1992-774	19920227
	US 5227293	A	19930713	US 1992-838221	19920423

	US 5358857	A	19941025	US 1993-73508	19930609
PRAI	US 1989-399874	A2	19890829		
	WO 1990-US4840	A	19900828		
	US 1992-838221	A1	19920423		

OS MARPAT 115:43507

AB A process for prepg. a fusion protein comprising a ballast **peptide** or protein and a desired protein consists of (1) constructing an **oligonucleotide** mixt. which encodes the ballast **peptide** /protein; (2) creating a gene bank by inserting the **oligonucleotide** mixt. into a vector such that it is functionally linked to a regulatory region and to the gene encoding the desired protein; (3) transforming host cells with the vectors, and selecting clones which produce the fusion protein in high yield. The **oligonucleotide** encoding the ballast **peptide**/protein comprises (DCD)x (D = A,G,T; x = 4-12). An example of such an oligonucleotide which was used to produce a proinsulin-contg. fusion protein in Escherichia coli is ATGGCD(DCD)yACGCGT (y = 3-6). The ballast peptide/protein does not interfere with folding of the desired protein, and is designed to produce a fusion protein which is sol. or easily solubilized.

L50 ANSWER 33 OF 34 HCAPLUS COPYRIGHT 2003 ACS

AN 1988:1549 HCAPLUS

DN 108:1549

TI Chemoenzymic synthesis of genes encoding medium-sized **polypeptides** by use of only one synthetic **oligonucleotide**

AU **Uhlmann, Eugen**; Hein, Friedrich

CS Hoechst A.-G., Frankfurt/Main, D-6230/80, Fed. Rep. Ger.

SO Nucleic Acids Symposium Series (1987), 18(Symp. Chem. Nucleic Acid Compon., 7th, 1987), 237-40
CODEN: NACSD8; ISSN: 0261-3166

DT Journal

LA English

AB A novel strategy for the synthesis of genes encoding medium-sized **polypeptides** from only one synthetic **oligodeoxynucleotide** is outlined. A 140-mer oligodeoxynucleotide forming a hairpin structure at its 3'-end was synthesized and successfully used in the construction and cloning of a gene coding for salmon calcitonin-gly (33). Employing this "one oligonucleotide - one gene" approach, the manual work required for oligodeoxynucleotide synthesis is reduced to a min.

L50 ANSWER 34 OF 34 HCAPLUS COPYRIGHT 2003 ACS

AN 1986:436849 HCAPLUS

DN 105:36849

TI Synthetic signal sequence for transport of proteins in expression systems

IN Engels, Joachim; Leineweber, Michael; **Uhlmann, Eugen**; Wetekam, Waldemar

PA Hoechst A.-G. , Fed. Rep. Ger.

SO Ger. Offen., 22 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3436818	A1	19860410	DE 1984-3436818	19841006
	EP 177827	A2	19860416	EP 1985-112043	19850923
	EP 177827	A3	19871202		
	EP 177827	B1	19931118		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 97445	E	19931215	AT 1985-112043	19850923
	HU 40164	A2	19861128	HU 1985-3761	19850930
	HU 197355	B	19890328		

	JP 61088883	A2	19860507	JP 1985-221120	19851003
	ES 547600	A1	19860316	ES 1985-547600	19851004
	DK 8504532	A	19860407	DK 1985-4532	19851004
	AU 8548333	A1	19860410	AU 1985-48333	19851004
	AU 595486	B2	19900405		
	IL 76573	A1	19920621	IL 1985-76573	19851004
	CA 1340280	A1	19981222	CA 1985-492345	19851004
PRAI	DE 1984-3436818		19841006		
	EP 1985-112043		19850923		

AB A synthetic signal peptide-coding DNA sequence is prepd. which contains endonuclease cleavage sites to permit its insertion into expression vectors. Coupling of a protein-coding gene with this sequence in the vector results in expression of the protein fused to the signal peptide, and in transport of the protein out the cell. For example, the signal DNA sequence for Escherichia coli alk. phosphatase was prepd. by ligation of synthetic oligonucleotides. A DNA was prepd. which contained a synthetic regulatory region (promoter, lac operator, ribosomal binding site) a recognition sequence for EcoRI, the signal DNA sequence, and the gene for proinsulin for cloning and expression in E. coli. The expressed proinsulin was secreted by cells.

=> fil wpix
FILE 'WPIX' ENTERED AT 12:30:12 ON 12 APR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE LAST UPDATED: 10 APR 2003 <20030410/UP>
MOST RECENT DERWENT UPDATE: 200324 <200324/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> SLART (Simultaneous Left and Right Truncation) is now
available in the /ABEX field. An additional search field
/BIX is also provided which comprises both /BI and /ABEX <<<

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
SEE http://www.derwent.com/dwpi/updates/dwpicov/index.html <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
http://www.derwent.com/userguides/dwpi_guide.html <<<

=> d all abeq tech abex l61

L61 ANSWER 1 OF 1 WPIX (C) 2003 THOMSON DERWENT
AN 2002-075055 [10] WPIX
DNC C2002-022297
TI New peptide nucleic acid derivatives, useful e.g. for tumor treatment and diagnosis, contain terminal, deprotonizable phosphoryl groups for e.g. improved solubility.
DC B04 D16
IN BREIPOHL, G; UHLMANN, E; WILL, D W
PA (AVET) AVENTIS PHARMA DEUT GMBH; (BREI-I) BREIPOHL G; (UHLM-I) UHLMANN E; (WILL-I) WILL D W
CYC 96
PI WO 2001079216 A2 20011025 (200210)* DE 93p C07H000-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

DE 10019135 A1 20011031 (200210) C07K007-00
AU 2001054795 A 20011030 (200219) C07H000-00
US 2002187473 A1 20021212 (200301) C12Q001-68 <--
NO 2002004959 A 20021015 (200305) C07H000-00
EP 1276760 A2 20030122 (200308) DE C07K014-00
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR
BR 2001010110 A 20030211 (200317) C07K014-00

ADT WO 2001079216 A2 WO 2001-EP4030 20010407; DE 10019135 A1 DE 2000-10019135 20000418; AU 2001054795 A AU 2001-54795 20010407; US 2002187473 A1 US 2001-835371 20010417; NO 2002004959 A WO 2001-EP4030 20010407, NO 2002-4959 20021015; EP 1276760 A2 EP 2001-927897 20010407, WO 2001-EP4030 20010407; BR 2001010110 A BR 2001-10110 20010407, WO 2001-EP4030 20010407

FDT AU 2001054795 A Based on WO 200179216; EP 1276760 A2 Based on WO 200179216; BR 2001010110 A Based on WO 200179216

PRAI DE 2000-10019135 20000418

IC ICM C07H000-00; C07K007-00; C07K014-00; C12Q001-68
ICS A61K038-00; A61K048-00; C07F009-40; C07K001-04; C07K017-02; C12Q001-02; C12Q001-70; G01N033-563; G01N033-569; G01N033-58

AB WO 200179216 A UPAB: 20020213

NOVELTY - New PNA (peptide nucleic acid) derivatives (A) having at the C-, optionally also the N-, terminus one or more phosphoryl (including oxo-, thiono- or imino-phosphoryl) groups, at least one of which contains one or more deprotonizable groups, preferably hydroxy or mercapto.

DETAILED DESCRIPTION - New PNA (peptide nucleic acid) derivatives (A) having at the C-, optionally also the N-, terminus one or more phosphoryl (including oxo-, thiono- or imino-phosphoryl) groups, at least one of which contains one or more deprotonizable groups, preferably hydroxy or mercapto. The phosphoryl groups are attached to the PNA backbone directly or through a spacer, by an oxygen-, sulfur- or nitrogen-phosphorus bond.

INDEPENDENT CLAIMS are also included for the following:

(1) detection reagent containing (A);

(2) PNA chip containing (A);

(3) biosensor containing (A);

(4) pharmaceutical composition containing (A) and optionally other additives and/or carriers;

(5) antisense, antigene, decoy or chimeraplast agents containing (A); and

(6) method for preparing (A).

ACTIVITY - Cytostatic; virucide; dermatological; antiasthmatic.

No biological data given.

MECHANISM OF ACTION - Inhibiting transcription or translation by hybridization.

No biological data given.

USE - (A) are useful for treatment of tumors (claimed) or (disclosed) generally any disease associated with (over)expression of particular genes, e.g. viral infection, vitiligo or other pigmentation disorders, and asthma; as diagnostic reagents; for detecting microorganisms and/or viruses; for detecting and/or quantifying nucleic acid; as reagents for (fluorescent) in-situ hybridization; as antisense, antigene, decoy or chimeraplast agents; and as molecular beacons.

ADVANTAGE - (A) can be produced in high yield and have improved solubility in water (particularly for lipophilic compounds), binding properties (affinity for complementary DNA or RNA) or cellular uptake, compared with uncharged PNAs. The ionizable groups allow them to be purified efficiently and also they migrate in electrical fields for microlocalization and concentration. A PNA targeted to the mRNA of Ha-ras having N-terminal phosphoryl, as mono-hexadecyl ester, and C-terminal 6-(phosphoryl)hexylamino (with fluorescein linked to phosphoryl) inhibited

growth of pre-B leukemia cells (DSM ACC 22) more effectively than the corresponding phosphorothioate oligonucleotide (no figures given).
Dwg.0/9

FS CPI

FA AB; GI; DCN

MC CPI: B04-E02; B04-E06; B04-E10; B04-F01; B04-F11; B12-K04A4; B12-K04E; B14-A02; B14-H01B; B14-K01A; B14-N17; D05-H09; D05-H12

TECH UPTX: 20020213

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Compounds: The spacer is an alkanoylamide, poly(alkoxy)carboxamide or amino acid. At least one phosphoryl group contains at least one hydroxy or mercapto that is deprotonized at pH 4.5-14, best 6.5-9, and is particularly a (thio)phosphate, phosphonate or phosphoramidate. It may be substituted by one or more labels, crosslinkers, groups that improve intracellular uptake or increase binding affinity for nucleic acid. Preferred (A) are of formula (I), or their salts.

where

q = 0 or 1;

each D' = hydroxy, mercapto, amino, alkylamino or acylamino;

each V, W and W' = oxygen, sulfur or NR1;

each V' = V or U-(CR3R4)u'-CONH or U-(CH2CH2O)u'-CH2CONH;

each U = oxygen, sulfur or NH;

u' = 1-10;

each Y and Y' = hydroxy, mercapto, oxyanion, thioate or NR1R2;

each X and X' = U(2-22C alkanediyl)U or U(CH2CH2O)u' or a functional group;

each Z' and Z'' = hydroxy, mercapto, oxyanion, thioate or NR1R2, 1-22C alkyl, aryl(1-8C)alkyl, 1-22C alkyl-U, hydroxy(1-18C)-U, aminoalkyl-U or mercaptoalkyl-U, or a functional group;

R1 and R2 = hydrogen or 1-6C alkyl;

R3 and R4 = hydrogen, 1-6C alkyl or amino acid sidechain, or together, in V', form a 5-8C cycloalkyl;

n and m = 0-10;

POLY = the group ((-BLOCK-CONH)z''-BLOCK-G-);

each BLOCK = any of 9 PNA-type residues;

z'' = 0-100;

G = any of several linking groups providing at least one Y, Y', Z or Z' is a hydroxy, mercapto, oxyanion, or thioate and at least one BLOCK must contain a nucleobase.

Functional groups for X and Z are labels, crosslinkers or groups that increase binding affinity or intracellular uptake.

Particularly (A) is directed against part of a tumor suppressor gene, oncogene or telomerase, or their transcription products, specifically against the translation initiation site of HA-ras mRNA. About 50 sequences for (A) are reproduced.

Preparation: The C-terminus of an amido-nucleic acid (ANA) is coupled to a phosphorylation reactant, on a solid phase, or a C-terminal phosphorylated ANA is coupled to a solid phase. The backbone of the PNA is extended by sequential coupling of ANA monomers, and optionally the N-terminus phosphorylated. Preferred carriers are controlled pore glass, a 'Tentacle' gel or aminomethylpolystyrene. The product can be purified by chromatography or electrophoresis, exploiting the acidic nature of the phosphoryl group, particularly using a basic stationary phase (anion exchanger or mixed mode material) and a gradient of acidic or salt-containing eluant.

ABEX UPTX: 20020213

SPECIFIC COMPOUNDS - Preparation of 7 (A) is described, e.g. MeCONH(CH2CH2N(COCH-2B)-CH2CONH)11-(CH2)6-O-P(=O)(O-)2 where the sequence of B is 5'-TATTCCGTCAT.

ADMINISTRATION - (A) are administered rectally, parenterally, orally etc., typically at 0.01-50 mg/kg/day.

EXAMPLE - A bis(hydroxyethyl)sulfonyl-derivatized glass carrier was reacted with a phosphoramidite that included a 6-(protected amino)hexyl linker, then the product oxidized (iodine) and essentially conventional synthesis of peptide nucleic acid (PNA) carried out. Free amino groups were blocked by acetylation then the product recovered by treatment with concentrated ammonia (deprotection and release from the carrier) and purified on a C18 column to give MeCONH(CH2CH2N(COCH-2B)-CH2CONH)11-(CH2)6-O-P(=O)(O-)2 where the sequence of B is 5'-TATTCCGTCAT.

=> d his

(FILE 'REGISTRY' ENTERED AT 11:48:48 ON 12 APR 2003)
DEL HIS
L1 STR
L2 STR
L3 STR L2
L4 50 S L3
L5 1080 S L3 FUL
SAV L5 SIEW835/A
L6 STR L2
L7 0 S L6 CSS SAM SUB=L5
L8 0 S L6 CSS FUL SUB=L5
SAV L8 SIEW835A/A
L9 1 S L1 SAM SUB=L5
L10 57 S L1 FUL SUB=L5
SAV L10 SIEW835B/A
L11 2 S L10 AND 6/NR
L12 2 S L10 AND 7/NR
L13 1 S L11 NOT OC5-C6/ES
L14 1 S L12 NOT 46.150.18/RID
L15 208 S L5 AND P/ELS
L16 122 S L15 AND 1/P
L17 4 S L16 AND 1/NR

FILE 'REGISTRY' ENTERED AT 12:00:37 ON 12 APR 2003

FILE 'HCAPLUS' ENTERED AT 12:01:57 ON 12 APR 2003
L18 7 S L13,L14,L17
L19 3 S L18 AND (UHLMANN ? OR BREIPOHL ? OR WILL D?)/AU
L20 3 S L18 AND HOECHST?/PA,CS
L21 3 S L19,L20
E US20020187473/PN
L22 1 S E3
SEL RN

FILE 'REGISTRY' ENTERED AT 12:04:30 ON 12 APR 2003
L23 63 S E1-E63
L24 0 S L23 AND L5
L25 0 S L23 NOT SQL/FA
L26 2 S L23 NOT UNSPECIFIED
L27 61 S L23 NOT L26
L28 11 S L27 AND PEPTIDE
L29 5 S L28 AND 22/SQL
L30 6 S L28 NOT L29
L31 4 S L30 NOT ISOBENZOFURAN
L32 3 S L31 NOT THIENO
L33 50 S L27 NOT L28

FILE 'HCAPLUS' ENTERED AT 12:14:20 ON 12 APR 2003
E HID
E UHLMANN E/AU
L34 179 S E3,E4,E14-E18

```
                E UEHLMANN E/AU
                E BRIEPOHL G/AU
                E BREIPOHL G/AU
L35          106 S E3-E6
                E BREIPOEHL G/AU
L36            1 S E2
                E WILL D/AU
L37           40 S E3,E7-E10
L38          275 S L34-L37
L39          274 S L38 NOT L22
                E PEPTIDE NUCLEIC ACID/CT
                E E4+ALL
L40         1717 S E3+NT
                E E2+ALL
L41         4496 S PEPTIDE(S)NUCLEIC ACID
L42         5022 S PNA
L43         8250 S L40-L42
L44        38606 S ?PEPTIDE?(S)(?NUCLEO? OR ?NUCLEI?)
L45        42349 S L43,L44
L46           37 S L38 AND L45
L47            7 S L18-L22 AND L45
L48            3 S L47 AND L38
L49            8 S L18-L22,L47,L48
L50           34 S L46 NOT L49
L51           41 S L18-L21,L46-L50 NOT L22

     FILE 'REGISTRY' ENTERED AT 12:24:29 ON 12 APR 2003

     FILE 'HCAPLUS' ENTERED AT 12:24:29 ON 12 APR 2003
                SET SMARTSELECT ON
L52          SEL L51 1- RN :     657 TERMS
                SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 12:24:30 ON 12 APR 2003
L53          657 S L52
L54          134 S L53 AND PEPTIDE AND NUCLEIC ACID
L55           90 S L54 NOT COMPLEX
L56            7 S L55 AND 6-7/NR
L57            5 S L56 NOT L13,L14,L17
L58           83 S L55 NOT L56
L59           43 S L58 NOT OH
L60           42 S L59 NOT XANTHEN?

     FILE 'HCAPLUS' ENTERED AT 12:28:50 ON 12 APR 2003

     FILE 'WPIX' ENTERED AT 12:29:13 ON 12 APR 2003
                E US20020187473/PN
L61            1 S E3

     FILE 'DPCI' ENTERED AT 12:29:54 ON 12 APR 2003
                E US20020187473/PN

     FILE 'WPIX' ENTERED AT 12:30:12 ON 12 APR 2003
```